HCV NS-3 serine protease inhibitors

Abstract

Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site. ##STR00001##

Claims

1. A compound of formula VIga: ##STR00163## wherein A is C(O)OR.sup.1 or C(O)NHSO.sub.2R.sup.2; wherein R.sub.1 is hydrogen or C.sub.1-C.sub.6alkyl; and R.sub.2 is C.sub.1-C.sub.6alkyl, C.sub.0-C.sub.6alkylcarbocyclyl, or C.sub.0-C.sub.3alkylheterocyclyl, each of which is optionally substituted with 1 to 3 substituents which are each independently halo, oxo, nitrile, azido, nitro, C.sub.1-C.sub.6alkyl, C.sub.0-C.sub.3alkylcarbocyclyl, C.sub.0-C.sub.3alkylheterocyclyl, NH.sub.2C(O), YNRaRb, YORb, YC(O)Rb, Y(CO)NRaRb, YNRaC(O)Rb, YNHSOpRb, YS(O)pRb, YS(O)pNRaRb, YC(O)ORb, or YNRaC(O)ORb; Y is independently a bond or C.sub.1-C.sub.3alkylene; p is independently 1 or 2; Ra is independently H or C.sub.1-C.sub.3alkyl; Rb is independently H, C.sub.1-C.sub.6alkyl, C.sub.0-C.sub.3alkylcarbocyclyl, or C.sub.0-C.sub.3alkylheterocyclyl; Rd is H or C.sub.1-C.sub.3alkyl; q is 0 and k is 1; Rz is H, or together with the asterisked carbon forms an olefinic bond; Rq is H or C.sub.1-C.sub.6alkyl; W is O or S; R.sub.8 is a ring system containing 1 or 2 saturated, partially saturated or unsaturated rings, each of which has 4-7 ring atoms and each of which has 0 to 4 hetero atoms selected from S, O, and N, the ring system being optionally spaced from W by a C.sub.1-C.sub.3alkyl group; any of which R.sup.8 groups can be optionally mono, di, or tri substituted with R.sup.9, wherein R.sub.9 is independently halo, oxo, nitrile, azido, nitro, C.sub.1-C.sub.6alkyl, C.sub.0-C.sub.3alkylcarbocyclyl, C.sub.0-C.sub.3alkylheterocyclyl, NH.sub.2C(O), YNRaRb, YORb, YC(O)Rb, Y(CO)NRaRb, YNRaC(O)Rb, Y-NHSOpRb, YS(O)pRb, YS(O)pNRaRb, YC(O)ORb, or YNRaC(O)ORb; wherein said carbocyclyl or heterocyclyl moiety is optionally substituted with R.sup.10; wherein R.sub.10 is C.sub.1-C.sub.6alkyl, C.sub.3-C.sub.7cycloalkyl, C.sub.1-C.sub.6alkoxy, amino, sulfonyl, (C.sub.1-C.sub.3 alkyl)sulfonyl, NO.sub.2, OH, SH, halo, haloalkyl, carboxyl, or amido; J is a single 3 to 10-membered saturated or partially unsaturated alkylene chain, which chain is optionally interrupted by one to three heteroatoms that are each independently O, S, or NR.sup.12, and wherein 0 to 3 carbon atoms in the chain are optionally substituted with R.sup.14; R.sub.12 is H, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6cycloalkyl, or COR.sup.13; R.sub.13 is C.sub.1-C.sub.6alkyl, C.sub.0-C.sub.3alkylcarbocyclyl, or C.sub.0-C.sub.3alkylheterocyclyl; each R.sup.14 is independently H, C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6haloalkyl, C.sub.1-C.sub.6alkoxy, hydroxyl, halo, amino, oxo, thio, or C.sub.1-C.sub.6 thioalkyl; G is O, NRy-, or NRjNRj-; Ry is H or C.sub.1-C.sub.3alkyl; Rj is H; U is O or is absent; R.sub.16 is H; or R.sup.16 is C.sub.1-C.sub.6alkyl, C.sub.0-C.sub.3alkylcarbocyclyl, or C.sub.0-C.sub.3alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C.sub.1-C.sub.6alkyl, C.sub.0-C.sub.3alkylcarbocyclyl, C.sub.0-C.sub.3alkylheterocyclyl, NH.sub.2CO, YNRaRb, YORb, YC(O)Rb, Y(CO)NRaRb, YNRaC(O)Rb, Y-NHSOpRb, YS(O)pRb, YS(O)pNRaRb, YC(O)ORb, or YNRaC(O)ORb; or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein R.sup.2 is C.sub.1-C.sub.6alkyl, C.sub.0-C.sub.3alkylaryl, C.sub.3-C.sub.7cycloalkyl, or phenyl, each of which is optionally substituted with 1 to 3 substituents which are each halo, oxo, nitrile, azido, nitro, C.sub.1-C.sub.6alkyl, C.sub.0-C.sub.3alkylcarbocyclyl, C.sub.0-C.sub.3alkylheterocyclyl, NH.sub.2C(O), YNRaRb, YORb, YC(O)Rb, Y(CO)NRaRb, YNRaC(O)Rb, Y-NHSOpRb, YS(O)pRb, YS(O)pNRaRb, YC(O)Orb, or YNRaC(O)ORb.

3. The compound according to claim 1, wherein said compound has the partial structure that is: ##STR00164##

4. The compound according to claim 3, wherein Rq is C.sub.1-C.sub.3 alkyl.

5. The compound according to claim 1, wherein A is C(O)OR.sup.1, wherein R.sup.1 is H or C.sub.1-C.sub.6 alkyl.

6. The compound according to claim 1, wherein W is O.

7. The compound according to claim 1 wherein R.sup.8 is optionally substituted C.sub.0-C.sub.3alkylcarbocyclyl or optionally substituted C.sub.0-C.sub.3alkylheterocyclyl.

8. The compound according to claim 7, wherein R.sup.8 is 1-naphthylmethyl, 2-naphthylmethyl, benzyl, 1-naphthyl, 2-napthyl, or quinolinyl any of which is unsubstituted, mono, or disubstituted with R.sup.9 as defined.

9. The compound according to claim 8, wherein R.sup.8 is: ##STR00165## wherein R.sup.9a is C.sub.1-C.sub.6alkyl; C.sub.1-C.sub.6alkoxy; thioC.sub.1-C.sub.3alkyl; amino optionally substituted with C.sub.1-C.sub.6alkyl; C.sub.0-C.sub.3alkylaryl; C.sub.0-C.sub.3alkylheteroaryl, or C.sub.0-C.sub.3alkylheterocyclyl, said aryl, heteroaryl or heterocycle being optionally substituted with R.sup.10 wherein R.sup.10 is C.sub.1-C.sub.6alkyl; C.sub.0-C.sub.3alkyl; C.sub.3-C.sub.7cycloalkyl; C.sub.1-C.sub.6alkoxy; amino optionally mono- or di-substituted with C.sub.1-C.sub.6alkyl; amide; or C.sub.1-C.sub.3alkylamide; and R.sup.9b is C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6-alkoxy, amino, di(C.sub.1-C.sub.3alkyl)amino, (C.sub.1-C.sub.3alkyl)amide, NO.sub.2, OH, halo, trifluoromethyl, or carboxyl.

10. The compound according to claim 9, wherein R.sup.9a is aryl or heteroaryl, either of which is optionally substituted with R.sup.10 as defined.

11. The compound according to claim 9, wherein R.sup.9a is: ##STR00166## wherein R.sup.10 is H; C.sub.1-C.sub.6alkyl; C.sub.0-C.sub.3alkylcycloalkyl; amino optionally mono- or di-substituted with C.sub.1-C.sub.6alkyl; amido; or (C.sub.1-C.sub.3alkyl)amide.

12. The compound according to claim 9, wherein R.sup.9a is optionally substituted phenyl.

13. The compound according to claim 9, wherein R.sup.9b is C.sub.1-C.sub.6-alkoxy.

14. The compound according to claim 1, wherein J is a 4 to 7-membered saturated or unsaturated, all carbon alkylene chain.

15. The compound according to claim 1, wherein R.sup.16 is H, C.sub.1-C.sub.6alkyl, or C.sub.3-C.sub.6cycloalkyl.

16. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier.

17. The pharmaceutical composition of claim 16, further comprising an additional HCV antiviral.

18. The pharmaceutical composition of claim 17, wherein the additional HCV antiviral is a nucleoside analogue polymerase inhibitor, a protease inhibitor, ribavirin, or interferon.

19. A method of treating hepatitis C virus (HCV) infection comprising administering to an individual afflicted with or at risk of HCV infection, an effective amount of a compound of claim 1.

20. The method of claim 19, further comprising administering to the individual, an additional HCV antiviral.

21. The method of claim 20, wherein the additional HCV antiviral is a nucleoside analogue polymerase inhibitor, a protease inhibitor, ribavirin, or interferon.

Description

DETAILED DESCRIPTION OF THE EMBODIMENTS

(1) Various embodiments of the invention will now be described by way of illustration only with reference to the following non-limiting examples.

Example 1

(2) ##STR00054##

7-Methoxy-2-phenyl-quinolin-4-ol (1)

(3) To a stirred round bottled flask with toluene (100 mL) ethyl benzoyl acetate (18.7 g, 97 mmol) and m-anisidine (12 g, 97 mmol) was added. 4 M HCl in dioxane (0.5 mL) was added and the reaction mixture was refluxed for 6 h (140 C.). The mixture was co-evaporated with toluene. To the crude mixture diphenyl ether (50 mL) was added and the mixture was heated to 280 C. for 2 h. When the theoretical amount ethanol (6 mL) was collected in a Dean Stark trap the heating was stopped and the mixture was cooled to rt. The crude mixture was dissolved in CH.sub.2Cl.sub.2 (100 mL) and stirred for 30 min. The formed precipitate was filtered off and dried which gave 1 (4.12 g, 16.4 mmol, 17%): pale yellow powder.

(4) .sup.1H (300 MHz, DMSO-D.sub.6): 3.8 (s, 3H), 6.24 (s, 1H), 6.88-6.96 (dd, 1H, J=9.07 Hz, J=2.47 Hz), 7.19 (d, 1H, J=2.19 Hz), 7.56 (t, 3H, J=2.19 Hz), 7.8 (dd, 2H, J=7.14 Hz, J=2.19 Hz), 8.0 (d, 1H, J=9.06 Hz); .sup.13C (75.5 MHz, DMSO-D.sub.6): 55.3, 99.6, 106.9, 113.1, 119.1, 126.4, 127.5, 128.8, 130.2, 134.1, 142.2, 149.4, 161.8, 176.4.

Example 2

(5) ##STR00055##

(Rac)-4-oxocyclopent-2-ene-1, 2-dicarboxylic acid dimethyl ester (2)

(6) (1R,2S)-4-oxo-cyclopentane-1, 2-dicarboxylic acid dimethyl ester (4.8 g, 23.8 mmol) and CuBr.sub.2 (11.9 g, 532 mmol) were dissolved in dry THF (70 mL) and the mixture was refluxed for two hours at 90 C. The formed CuBr was filtrated off and the organic phase was concentrated. CaCO.sub.3 (2.7 g, 27.2 mmol) and DMF (70 mL) were added and the mixture was held at 100 C. for one hour. The dark brown mixture was poured over ice (35 g) and the formed precipitate was filtrated off. The aqueous layer was extracted with ethyl acetate (1300 mL+3150 mL). The organic phases were dried, filtrated and concentrated. Purification by flash chromatography (toluene/EtOAc 9:1) gave 2 (2.1 g, 45%) as yellow crystals

Example 3

(7) ##STR00056##

((1S,4R) & (1R,4S))-4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic add dimethyl ester (3)

(8) To a cold solution (30 C.) of 2 (3.18 g, 16.1 mmol) dissolved in MeOH (23 mL), NaBH.sub.4 (0.66 g, 17.5 mmol) was added. After nine minutes the excess of NaBH.sub.4 was destroyed by adding brine (80 mL). The mixture was concentrated and extracted with ethyl acetate (480 mL). The organic phases were dried, filtrated and concentrated and gave 3 (3.0 g, 92%) as a yellow oil.

Example 4

(9) ##STR00057##

(1 S,4R) & (1R,4S)-4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic add 2-methyl ester (4)

(10) To an ice-cold solution of 3 (3.4 g, 22 mmol) dissolved in dioxane and water (1:1, 110 mL), LiOH (0.52 g, 22 mmol) was added. After two and a half hours the mixture was co-evaporated with toluene and methanol. Purification by flash chromatography (toluene/Ethyl acetate 3:1+1% HOAc) gave the title compound (1.0 g, 27%) as yellow-white crystals.

(11) .sup.1H-NMR (300 MHz, CD.sub.3OD): 1.78-1.89 (m, 1H), 2.70-2.84 (m, 1H), 3.56-3.71 (m, 1H), 3.76 (s, 3H), 4.81-4.90 (m, 1H), 6.76-6.81 (m, 1H); .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 38.0, 48.0, 52.4, 75.7, 137.0, 148.2, 165.0 178.4.

Example 5

(12) ##STR00058##

((3S,5R) & (3R,5S))-5-((S)-1-tert-Butoxycarbonyl-butylcarbamoyl)-3-hydroxy-cyclopent-1-enecarboxylic acid methyl (5)

(13) To an ice cooled solution of 4 (0.20 g, 1.1 mmol) and 2-amino-pentanoic add tert.butyl ester (0.24 g, 1.4 mmol) in DMF (7 mL), DIPEA (0.18 g, 1.4 mmol) and HATU (0.53 g, 1.4 mmol) were added. After two hours the solution was concentrated and purified using column chromatography (toluene/ethyl acetate 3:1). This gave the title compound as a yellow oil (0.22 g, 63%).

(14) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.84-0.96 (m, 3H), 1.14-1.39 (m, 2H), [(1.44 & 1.49) s, 9H], 1.50-1.60 (m, 1H), 1.61-1.85 (m, 1H), 1.97-2.10 (m, 1H), 2.11-2.28 (m, 1H), 3.57-3.68 (m, 1H), [(3.73 & 3.76) s, 3H], 4.30-4.50 (m, 1H), 4.63-4.73 (m, 1H), 6.8068.95 (m, 1H), 6.95-7.00 (m, 1H).

Example 6

(15) ##STR00059##

((3S,5R) & (3R,5S))-5-((S)-1-tert-Butoxycarbonyl-propylcarbamoyl-3-hydroxy-cyclopent-1-necarboxylic acid methyl ester (6)

(16) Reaction of 4 (141 mg, 76 mmol) according to the method described for the preparation of 5 using L-2-amino-N-butyric acid tert.butyl ester instead of 2-amino-pentanoic acid tert.butyl ester gave the title compound as a slightly yellow oil (171 mg, 69%).

(17) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.89-0.98 (m, 3H), [(1.42 & 1.44) s, H], 1.60-1.78 (m, 1H), 1.79-1.95 (m, 1H), 1.99-2.11 (m, 1H), 2.18-2.30 (m, 1H), 3.58-3.65 (m, 1H), [3.75 & 3.78) s, 3H], 4.22-4.39 (m, 1H), 4.61-4.66 (m, 1H), 6.77-6.90 (m, 1H), 6.91-6.92 (m, 1H).

Example 7

(18) ##STR00060##

((3S,5R) & (3R,6S))-5-((1R,2S)-1-tert-Butoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-3-hydroxy-cyclopent-1-enecarboxylic acid methyl ester (7)

(19) Reaction of 4 (50 mg, 37 mmol) according to the method described for the preparation of 5 using (1R, 2S)-1-amino-2-vinyl-cyclopropane carboxylic acid tert.butyl ester instead of 2-amino-pentanoi acid tert.butyl ester provided the title compound as a slightly yellow oil (650 mg, 38%).

(20) .sup.1H-NMR (300 MHz, CDCl.sub.3): [(1.38 & 1.42) s, 9H], 1.75-1.83 (m, 1H), 2.00-2.21 (m, 3H), 3.55-3.63 (m, 1H), [(3.77 & 3.82) s, 3H], 4.20-4.38 (m, 1H), 4.65-4.80 (m, 1H), 5.13-5.20 (m, 1H), 5.22-5.38 (m, 1H), 5.60-6.82 (m, 1H), 6.95-8.96 (m, 2H).

Example 8

(21) ##STR00061##

((3R,5R) & (3S,5S))-5-((S)-1-tert-Butoxycarbonyl-butylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid methyl ester (8)

(22) To an ice cooled solution of 5 (0.23 g, 0.67 mmol) in dry THF, 7-methoxy-2-phenyl-quinolin-4-ol (0.22 g, 0.88 mmol) and triphenylphosphine (0.23 g, 0.88 mmol) were added. Then DIAD (0.19 g, 0.92 mmol) was dissolved in THF (2 mL) and added dropwise to the solution. After one hour the mixture was concentrated and purified using flash chromatography (toluene/ethyl acetate 3:1). This gave the title compound as a white powder (0.30 g, 77%).

(23) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.88-1.00 (m, 3H), 1.18-1.43 (m, 2H), [(1.45 & 1.50) s, 9H], 1.53-1.65 (m, 1H), 1.68-1.85 (m, 1H), 2.29-2.43 (m, 1H), 3.10-3.25 (m, 1H), [(3.79 & 3.83) s, 3H], 3.97 (s, 3H), 4.05-4.20 (m, 1H), 4.38-4.50 (m, 1H), 6.03-6.13 (m, 1H), 6.65-8.90 (m, 1H), 7.04-7.18 (m, 3H), 7.40-7.56 (m, 4H), 8.00-8.12 (m, 3H).

Example 9

(24) ##STR00062##

((3R,5R) & (3S,5S))-5-((S)-1-tert-Butoxycarbonyl-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid methyl ester (9)

(25) Reaction of 6 (132 mg, 40 mmol) according to the method described for the preparation of 8 gave the title compound as a yellow oil (137 mg, 61%).

(26) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.83-0.98 (m, 3H), [(1.42 & 1.44) a, 9H], 1.65-1.78 (m, 1H), 1.80-1.97 (m, 1H), 2.30-2.40 (m, 1H), 3.05-3.20 (m, 1H), [(3.78 & 3.80) s, 3H], 3.94 (s, 3H), 3.95-4.01 (m, 1H), 4.38-4.44 (s, 1H), 6.05-6.15 (m, 1H), 6.80-6.94 (m, 1H), 7.02-7.15 (m, 3H), 7.38-7.55 (m, 4H), 7.97-8.18 (m, 3H).

Example 10

(27) ##STR00063##

((3R,5R) & (3S,5S))-5-((1R,2S)-1-tert-Butoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid methyl ester (10)

(28) Reaction of 7 (41 mg, 116 mmol) according to the method described for the preparation of 8 provided the title compound as a yellow oil.

(29) .sup.1H-NMR (300 MHz, CDCl.sub.3): 1.52-1.57 (m, 1H), 1.58 (m, 9H), 1.80-1.83 (m, 1H), 2.00-2.17 (m, 1H), 2.20-2.38 (m, 1H), 3.20-3.37 (m, 1H), 3.80 (s, 3H), 3.81-3-3.98 (m, 1H), 3.99 (s, 3H), 5.12-6.20 (m, 1H), 5.22-5.40 (m, 1H), 5.63-5.80 (m, 1H), 6.05-6-20 (m, 1H), 7.00-7.21 (m, 4H), 7.40-7.58 (m, 4H), 8.02-8.18 (m, 3H).

Example 11

(30) ##STR00064##

((3R,5R) & (3S,5S)-5-((S-1-tert-Butoxycarbonyl-butylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid (11)

(31) The methyl ester 8 (0.35 g, 0.61 mmol) was dissolved in dioxane/water (1:1, 7 mL) and LiOH (0.031 g, 1.3 mmol) was added. The reaction was stirred over night and then co-concentrated. This gave the lithium salt of 11 (0.32 g, 90%) as a brown powder.

Example 12

(32) ##STR00065##

((3R,5R)& (3S,5S))-5-((S)-1-tert-Butoxycarbonyl-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid (12)

(33) Reaction of 9 (225 mg, 40 mmol) according to the method described for the preparation of 11 provided the title compound as yellow salt (157 mg, 72%).

Example 13

(34) ##STR00066##

((3R,5R) & (3S,5S))-5-((1R,2S)-1-tert-Butoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic Acid (13)

(35) Reaction of 10 (35 mg, 59 mmol) according to the method described for the preparation of 11 (33 mg, 97%) provided the title compound as a yellow salt.

Example 14

(36) ##STR00067##

(S)-2-{[((1R,4S) & (1R,4R))-2-{(S)-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric acid tert-butyl ester (14)

(37) The add 12 (38.4 mg, 0.070 mmol) and (2-amino-3-methyl-butyrylamino)-cyclohexyl acetic acid methyl ester (26.6 mg, 0.098 mmol) were dissolved in DMF (1.5 mL) and cooled in an ice-bath. DIPEA (17.1 L, 0.096 mmol) and HATU (37.4 mg, 0.098 mmol) were added. After ninety minutes the mixture was co-concentrated with toluene and methanol and then purified by lash column chromatography (toluene/ethyl acetate 6:1). Further purification was performed on HPLC (90% MeOH+0.2% TEA). The diastereomeric mixture 14 was concentrated and gave a slightly yellow oil (20.6 mg, 37%). After lyophilisation 14 was collected as a white powder. .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.93-1.02 (m, 9H), 1.03-1.25 (m, 4H), 1.44 (s, 9H), 1.65-1.86 (m, 9H), 2.05-2.10 (m, 1H), 2.22-2.40 (m, 1H), 3.05-3.20 (m, 1H), 3.77 (s, 3H), 3.98 (s, 3H), 4.18-422 (m, 1H), 4.38-4.60 (m, 3H), 6.01-6.10 (m, 1H), 6.61-6.70 (m, 2H), 6.80-6.85 (m, 1H), 7.05-7.18 (m, 2H), 7.40-7.58 (m, 5H), 8.00-8.13 (m, 3H). .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 9.7, 18.4, 19.2, (25.9 & 26.11, [28.2 & 28.5], 29.6, 32.0, 37.3, 41.0, 46.2, 50.7, 52.4, 54.4, 55.8, 57.2, 58.5, 82.0, 82.8, 98.4, 110.2, 118.4, 120.1, 123.2, 127.9, 128.2, 128.9, 129.5, 131.2, 135.1, 135.2, 142.7, 144.2, 161.6, 164.3, 164.7, 170.9, 171.4, 172.4. MALDI-TOF m/z 821.56 [(M+Na).sup.+ calcd for C.sub.45H.sub.58N.sub.4NaO.sub.9.sup.+ 821.41].

Example 15

(38) ##STR00068##

(S)-2-[((1R,4R) & (1 S,4S))-2-{(R)-1-[((R)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-butyric add tert-butyl eater (15)

(39) Reaction of 12 (20 mg, 37 mmol) according to the method described for the preparation of 14 using (2-amino-3-methyl-butyrylamino)-(R)-cyclohexyl acetic acid methyl ester instead of (2-amino-3-methyl-butyrylamino)-(S)-cyclohexyl acetic acid methyl ester, gave the title compound (19 mg, 66%) as a white powder.

(40) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.91-0.98 (m, 3H), 0.99-1.10 (m, 6H), 1.11-1.38 (m, 4H), [(1.43 & 1.45) s, 9H], 1-45-1.94 (m, 9H), 2.05-2.18 (m, 1H), 2.22-2.40 (m, 1H), 3.16-3.24 (m, 1H), 3.77 (s, 3H), 3.98 (s, 3H), 4.04-4.18 (m, 1H), 4.36-4.57 (m, 3H), 6.00-4.08 (m, 1H), 6.13-6.21 (m, 1H), 6.62-6.70 (m, 1H), 8.81-6.85 (m, 1H), 7.05-7.18 (m, 3H), 7.41-7.57 (m, 4H), 8.02-8.13 (m, 3H). .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 9.3, 18.2, 19.0, [25.5 & 25.9], [28.0 & 28.3], 29.4, 31.4, 32.1, 35.7, 40.7, 50.4, 52.2, 54.2, 55.5, 57.0, 58.2, 81.8, 82.4, 982, 107.5, 115.0, 118.1, 122.9, 127.6, 128.7, 128.8, 128.9, 129.2, 135.1, 140.4, 142.2, 151.4, 181.3, 163.9, 170.4, 170.9, 171.2, 172.0. MALDI-TOF m/z 821.60 [(M+Na).sup.+ calcd for C.sub.45H.sub.58N.sub.4NaO.sub.9.sup.+ 821.41].

Example 16

(41) ##STR00069##

(S)-2-{[((3R,5R) & (3S,5S))-5-((S)-1-tert-Butoxycarbonyl-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarbonyl]-amino}-3-methyl-butyric acid methyl ester (16)

(42) Reaction of 12 (24 mg, 44 mmol) according to the method described for the preparation of 14 using D-valine methyl ester instead of (2-amino-3-methyl-butyrylamino)cyclohexyl acetic acid methyl ester, gave the title compound (27 mg, 97%) as a white powder.

(43) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.82-0.99 (m, 9H), [(1.42 & 1.44) s, 9H] 1.65-1.95 (m, 2H), 2.18-2.25 (m, 1H), 2.26-2.40 (m, 1H), 3.20-3.25 (m, 1H), 3.75 (s, 3H), 3.97 (s, 3H), 4.15-4.19 (m, 1H), 4.36-4.43 (m, 1H), 4.64-4.75 (m, 1H), 6.03-6.15 (m, 1H), 6.80-6.85 (m, 2H), 7.10-7.20 (m, 3H), 7.42-7.58 (m, 4H), 8.0-8.10 (m, 3H). .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 9.7, [18.2 & 19.1], 25.7, [28.1 & 28.2], 32.0, 35.6, 50.4, 52.4, 54.5, 55.7, 57.6, 81.7, 82.7, 98.4, 107.7, 115.2, 118.4, 123.2, 127.8, 129.0, 129.2, 129.5, 134.8, 135.0, 140.4, 142.5, 151.6, 159.6, [161.1 & 161.5], 164.6, 171.1, 172.2. MALDI-TOF m/z 682.51[(M+Na).sup.+ calcd for C.sub.37H.sub.45N.sub.3NaO.sub.8.sup.+ 682.31].

Example 17

(44) ##STR00070##

(S)-2-{[(1R,4R) & (1 S,4S))-2-{(S)-1-[(2,5-Dimethoxy-phenyl)-ethyl-carbamoyl]-2-methyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric acid tert-butyl ester (17)

(45) Compound 17 (28.6 mg, 59%) was prepared from 12 (33 mg, 60 mmol) according to the method for the preparation of 14 using 2-amino-N-(2,5-dimethoxy-phenyl)-N-ethyl-3-methyl butyramide instead of (2-amino-3-methyl-butyrylamino)-cyclohexyl acetic add methyl ester. This gave the title compound as a white powder.

(46) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.75-0.95 (m, 9H) 1.05-1.18 (m, 3H), [(1.42 & 1.44) s, 9H], 1.60-1.95 (m, 3H), 2.20-2.40 (m, 1H), 3.20-3.34 (m, 1H), 3.60-3.80 (m, 2H), [3.62-3.65 (m, 3H)], [3.79-3.82 (m, 3H)], 3.98 (s, 3H), 4.024-18 (m, 1H), 4.30-4.44 (m, 2H), 6.05-6.18 (m, 1H), 6.60-6.63 (m, 1H), 6.77-6.80 (m, 2H), 6.85-6.93 (m, 2H), 7.12-7.20 (m, 2H), 7.35-7.60 (m, 5H), 8.02-8.20 (m, 3H). .sup.13C-NMR (75.5 MHz, CDCl.sub.3): [9.6 & 9.7], [12.5 & 12.8], [17.1 & 17.5], [19.4 & 19.5], 25.6, [28.0 & 28.1], 32.4, 35.8, 43.0, 44.3, [50.2 & 50.3], 54.3, [54.8 & 55.0 & 55.2 & 55.5], [55.6 & 55.7 & 55.9 & 56.0], 81.7, 82.8, 98.4, 106.9, [112.4 & 112.5], 113.7, 115.0, 115.2, 115.9, 116.3, 118.4, [123.0 & 123.1], [127.7 & 127.8], 128.8, 128.9, 129.5, 130.1, [134.1 & 134.2], 142.6, 149.1, 149.4, 153.4, 158.9, [161.4 & 161.6], [163.2 & 163.5], 170.9, [171.3 & 171.5], 172.3. MALDI-TOF m/z 831.62 [(M+Na).sup.+ calcd for C.sub.46H.sub.56N.sub.4NaO.sub.9.sup.+ 831.39].

Example 18

(47) ##STR00071##

(S)-2-{[((1R,4R) &(1 S,4S))-2-{(S)-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric add tert-butyl ester (18)

(48) Compound 18 (16.1 mg, 26%) was prepared from 12 (43.2 mg, 0.077 mmol) according to the method for the preparation of 14 using (2-amino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester instead of (2-amino-3-methyl-butyrylamino)-cyclohexyl acetic acid methyl ester. Flash column chromatography was performed in toluene/ethyl acetate 3:1 instead of 6:1: This gave the title compound as a white powder.

(49) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.77-0.83 (m, 3H), [(0.92 & 0.93) s, 9H] 0.94-1.20 (m, 4H), [(1.36 & 1.38) s, 9H], 1.42-1.76 (m, 8H), 2.20-2.38 (m, 1H), 2.81-2.96 (m, 1H), 3.20-3.22 (m, 1H), 2.78 (s, 3H), [(3.83 & 3.85) a, 3H], 3.97-4.02 (m, 1H), 4.17-4.21 (m, 1H), 4.22-4.37 (m, 2H), 5.85-5.97 (m, 1H), [6.76-6.78 (m, 0.5H)], [6.80-6.82 (m, 0.5H)], 6.98-7.05 (m, 3H), 7.23-7.41 (m, 8H), 7.82-7.99 (m, 3H). .sup.13C-NMR (75.5 MHz, CDCl.sub.3): [9.4 & 9.5], [25.4 & 25.5], 25.8, [26.5 & 26.6], [27.9 & 28.0], [28.4 & 28.51, 29.3, (35.4 & 35.7], [36.0 & 36.4], [40.5 & 40.7], [50.2 & 50.5), [52.1 & 52.2], 154.1 & 54.3], 55.5, [57.0 & 57.3], [60.4 & 60.7], [81.8 & 82.0], [82.4 & 82.5] 98.1, 107.5, 115.0, 118.1, 123.0, 127.5, 128.7, 128.8, 129.2, 134.9, 135.8, 141.9, 142.5, 151.3, 159A, [160.9 & 161.3], [163.7 & 163.9], [169.9 & 170.0] [170.0 & 171.3], [172.5 & 172.4]. MALDI-TOF m/z 835.68 [(M+Na).sup.+ calcd for C.sub.46H.sub.60N.sub.4NaO.sub.9.sup.+ 835.43].

Example 19

(50) ##STR00072##

(S)-2-{[(1R,4R)-2-{(S)-1-[((S)-Cyclohexyl-ethoxycarbonyl-methyl)-carbamoyl]-2-methy-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-pentanoic acid tert-butyl ester (19a) and (S)-2-{[(1 S,4S)-2-((S)-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl}(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-pentanoic add tert-butyl eater (19b)

(51) The add 11 (0.051 g, 0.087 mmol) and (2-amino-3-methyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (0.054 g, 0.21 mmol) were dissolved in DMF (1.5 mL) and cooled in an ice-bath. DIPEA (16 mg, 0.12 mmol) and HATU (47 mg, 0.13 mmol) were added. After two and a half hours the mixture was co-concentrated with toluene and methanol and then purified by flash column chromatography (toluene/ethyl acetate 3:1). Further purification was performed on HPLC (90% MeOH+0.2% TEA). This gave after co-concentration the two diastereomers 19a (9.4 mg, 13%) and 19b (5.3 mg, 7%) as slightly yellow syrups. After lyophilisation 19a and 19b were collected as white powders:

(52) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.86-0.93 (m, 3H), 0.94-1.00 (m, 6H), 1.00-1.41 (m, 7H), 1.46 (s, 9H), 1.50-1.88 (m, 8H), 2.05-2.20 (m, 1H), 2.20-2.37 (m, 1H), 3.12-3.25 (m, 1H), 3.73 (s, 3H), 3.97 (s, 3H), 4.05-4.20 (m, 1H), 4.40-4.55 (m, 3H), 6.02-6.18 (m, 1H), 6.30 (d, J=8.52 Hz, 1H), 6.63 (s, 1H), 6.76 (d, J=8.51 Hz, 1H), 7.08-7.18 (m, 2H), 7.42-7.56 (m, 5H), 8.00-8.12 (m, 3H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 14.0, 18.4, 19.3, 26.1, 28.3, 28.5, 29.7, 31.9, 34.9, 36.0, 41.0, 50.7, 52.4, 53.3, 55.7, 57.2, 58.6, 82.0, 82.7, 98.4, 105.7, 107.7, 115.2, 118.4, 123.2, 125.3, 127.9, 129.0, 129.1, 135.1, 138.0, 142.4, 151.6, 159.4, 161.6, 164.3, 170.7, 171.2, 172.3. 19b: .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.90-1.04 (m, 9H), 1.04-1.43 (m, 7H), 1.47 (s, 9H), 1.50-1.87 (m, 8H), 2.10-2.27 (m, 1H), 2.33-2.45 (m, 1H), 3.10-3.20 (m, 1H), 3.73 (s, 3H), 3.96 (s, 3H), 4.02-4.10 (m, 1H), 4.36-4.53 (m, 3H), 6.00-6.16 (m, 1H), 6.30 (d, J=8.52 Hz, 1H), 6.73 (s, 1H), 6.86 (d, J=7.96 Hz, 1H), 7.08-7.16 (m, 2H), 7.36-7.56 (m, 5H), 8.03-8.11 (m, 3H). .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 14.0, 18.6, 19.2, 26.1, 28.2, 28.7, 29.7, 34.5, 36.1, 36.6, 40.8, 50.5, 52.4, 53.4, 55.7, 57.3, 59.1, 64.8, 82.3, 98.4, 105.8, 107.8, 115.3, 118.4, 123.2, 127.8, 129.0, 129.4, 135.2, 1422, 144.9, 151.0, 151.6, 159.2, 164.3, 164.3, 170.2, 171.6, 171.9

Example 20

(53) ##STR00073##

(S)-2-{[(1R,4R)-2-((R)-1-[((S)-Cyclohexyl-methoxycarbonyl-methy)-carbamoyl]2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-pentanoic acid tert-butyl ester (20a) and (S)-2-{[(1 S,4S)-2-{(R)-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-pentanoic acid tert-butyl ester (20b)

(54) Method A:

(55) The carboxylic acid 11 (57 mg, 0.10 mmol) was dissolved in warm (50 C.) dry THF (2 mL). (2-Amino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic add methyl ester (50 mg, 0.12 mmol), DIPEA (30 mg, 0.23 mmol), DCC (25 mg, 0.12 mmol) and HOBt (17 mg, 13 mmol) were added. After two hours the mixture was concentrated and added to a short column (toluene/Ethyl acetate 1:3+3% AcOH). Then it was further purified on HPLC using 90% MeOH+0.2% TEA. The diastereomeric products were not separated. After HPLC the solution was co-concentrated with toluene and methanol to give 20 (28 mg, 34%).

(56) Method B:

(57) To an ice-cold solution of 11 (60 mg, 0.10 mmol) and (2-amino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (42 mg, 0.15 mmol) DIPEA (19 mg, 0.15 mmol) and HATU (62 mg, 0.16 mmol) were added. After two and a half hours the mixture was concentrated and purified using column chromatography. (toluene/Ethyl acetate 3:1). The diastereomeric mixture was separated using HPLC (90% MeOH+0.2% TEA). This gave 20a (6 mg, 6%) and 20b (9 mg, 10%).

(58) 20a: .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.82-0.90 (m, 3H), 1.01 (s, 9H), 1.05-1.40 (m, 7H), 1.46 (s, 9H), 1.50-1.80 (m, 8H), 2.20-2.35 (m, 1H), 3.07-3.25 (m, 1H), 3.73 (s, 3H), 3.97 (s, 3H), 4.11 (d, J=7.96 Hz, 1H), 4.38-4.52 (m, 3H), 6.03-6.12 (m, 1H), 6.24 (d, J=8.79 Hz, 1H), 6.63 (s, 1H), 6.82 (d, J=9.06 Hz, 1H), 7.07-7.27 (m, 2H), 7.36 (d, J=7.96 Hz, 1H), 7.41-7.55 (m, 4H), 8.01-8.10 (m, 3H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 14.0, 18.8, 26.1, 26.8, 28.2, 28.6, 29.6, 34.9, 35.6, 36.2, 40.9, 50.7, 52.4, 53.3, 55.7, 57.3, 60.8, 82.0, 82.7, 98.4, 105.2, 107.7, 115.2, 118.4, 123.2, 127.9, 129.0, 129.4, 131.1, 135.1, 138.4, 142.4, 153.3, 1569.6, 161.6, 164.2, 170.1, 171.3, 172.2. 20b: .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.90-0.98 (m, 3H), 1.04 (s, 9H), 1.08-1.40 (m, 7H), 1.44 (s, 9H), 1.55-1.90 (m, 8H), 2.20-2.38 (m, 1H), 3.10-3.22 (m, 1H); 3.73 (s, 3H), 3.97 (s, 3H), 4.02-4.15 (m, 1H), 4.35-4.48 (m, 3H), 6.00-6.08 (m, 1H), 6.72 (s, 1H), 6.90 (d, J=9.06 Hz, 1H), 7.09-7.20 (m, 3H), 7.44-7.55 (m, 5H), 8.03-8.11 (m, 3H).

Example 21

(59) ##STR00074##

(1R,2S)-1-{[((1R,4R) & (1 S,4S))-2-{(S)-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid tert-butyl ester (21)

(60) The acid 13 (35 mg, 0.060 mmol) and (2-amino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (22 mg, 0.080 mmol) were dissolved in dry THF (1.5 mL) and warmed to 50 C. HOBt (11 mg, 0.080 mmol) and DCC (31 mg, 0.15 mmol) were added. After one hour the mixture was co-concentrated with toluene and methanol and then purified by flash column chromatography (toluene/ethyl acetate 1:1). Further purification was performed on HPLC (80% MeOH+0.2% TEA. The diastereomeric mixture 21 was concentrated and gave a slightly yellow oil (26.4 mg, 53%). After lyophilisation 21 was collected as a white powder.

(61) .sup.1H-NMR (300 MHz, CDCl.sub.3): [(0.98 & 1.00), s, 9H], 1.01-1.38 (m, 5H), [(1.39 & 1.40) s, 9H], 1.52-1.63 (m, 4H), 1.65-1.80 (m, 4H), 1.90-2.05 (m, 1H), 2.20-2.40 (m, 1H), 3.02-3.20 (m, 1H), [(3.66 & 3.67) s, 3H), 3.98 (s, 3H), 3.99-4.02 (m, 1H), 4.30-4.45 (m, 2H), 5.05-5.11 (m, 1H), 5.20-5.30 (m, 1H), 5.60-5.81 (m, 1H), 6.03-6.17 (m, 1H), 6.77-6.82 (m, 1H), 6.95-7.22 (m, 5H), 7.40-7.50 (m, 4H), 8.01-8.10 (m, 3H). .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 22.3, [25.7 & 25.8], [26.4 & 26.5], [28.0 & 28.4] 29.2, 32.7, 33.3, (35.3 & 35.4], 36.0, [40.2 & 40.3], 40.7, 52.0, 55.4, [57.2 & 57.4] [60.4 & 60.5], [87.6 & 87.7], [82.3 & 82.5], 98.4, 107.0, 114.9, [117.4 & 117.5], 118.1, 122.9, 127.6, 128.8, 128.9, 129.2, [133.6 & 133.8], 135.9, 136.9, 140.1, [141.4 & 141.6], 151.1, 159.6, [160.9 & 161.3], [164.2 & 164.6], 168.9, 170.3, [172.1 & 172.6]. MALDI-TOF m/z 859.77 [(M+Na).sup.+ calcd for C.sub.48H.sub.60N.sub.4NaO.sub.9.sup.+ 859.43].

Example 22

(62) ##STR00075##

(S)-2-{[(1R,4R)-2-{(R)-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-pentanoic add (22a) and (S)-2-{[(1 S,4S)-2-{(R)-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-pentanoic acid (22b)

(63) The tert.butyl ester 20 (28 mg, 0.034 mmol), TES (8.7 mg, 0.075 mmol), DCM (1 mL) and TFA (1 mL) were mixed in a round bottomed flask. Two hours later the mixture was concentrated and the diastereomers were separated on HPLC using 65% MeOH+0.2% TEA as mobile phase. This gave 22a (15 mg, 65%) and 22b (12 mg, 45%) as slightly yellow syrups. After lyophilisation the title compounds were collected as white powders.

(64) 22a: [].sup.22D+155.8; .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.90-0.97 (m, 3H), 1.03 (s, 9H), 1.05-1.50 (m, 7H), 1.50-1.80 (m, 8H), 2.43-2.55 (m, 1H), 2.77-2.90 (m, 1H), 3.68 (s, 3H), 3.96 (s, 3H), 4.20-4.30 (m, 2H), 4.31-4.40 (m, 1H), 4.45-4.50 (m, 1H), 6.03-6.11 (m, 1H), 6.98 (s, 1H), 7.12-7.19 (m, 1H), 7.36 (s, 1H), 7.41 (d, J=22 Hz, 1H), 7.50-7.60 (m, 3H), 8.03-8.10 (m, 3H): .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 13.1, 19.1, 26.1, 28.7, 28.9, 29.5, 34.3, 34.8, 35.9, 40.1, 50.8, 51.2, 54.8, 55.0, 57.9, 60.7, 83.5, 99.1, 106.0, 115.2, 118.2, 123.3, 127.8, 128.0, 128.7, 128.8, 129.7, 135.2, 139.8, 143.7, 150.6, 160.1, 162.2, 165.2, 171.7, 172.2, 173.4. 22b: [].sup.22D 72.3; .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.90-0.97 (m, 3H), 1.02 (s, 9H), 1.07-1.35 (m, 7H), 1.53-1.90 (m, 8H), 2.46-2.61 (m, 1H), 2.76-2.88 (m, 1H), 3.69 (s, 3H), 3.96 (s, 3H), 4.15-4.35 (m, 2H), 4.37-4.41 (m, 1H), 4.42-4.47 (m, 1H), 6.02-6.12 (m, 1H), 7.02 (s, 1H), 7.16 (dd, J=2.47, 9.34 Hz, 1H), 7.32 (s, 1H), 7.40 (d, J=2.47 Hz, 1H), 7.48-7.58 (m, 3H), 8.03-8.12 (m, 3H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 13.0, 18.8, 25.9, 26.0, 28.8, 29.4, 34.2, 34.8, 36.3, 39.9, 48.8, 50.5, 51.1, 54.8, 57.9, 60.5, 82.8, 99.0, 106.0, 115.1, 118.2, 123.1, 127.8, 127.9, 128.7, 129.0, 129.5, 136.7, 139.8, 142.8, 150.6, 160.1, 162.0, 162.2, 164.7, 172.1, 173.5.

Example 23

(65) ##STR00076##

(S)-2-{[(1R,4R)-2-{(R)-1-[((R)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methy-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric add (23a) and (S)-2-{[(1 S,4S)-2-{(R)-1-[((R)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric acid (23b)

(66) Compound 23a (6.6 mg, 50%) and compound 23b (1.3 mg, 10%) were prepared from 15 (14 mg, 0.018 mmol) according to the method for the preparation of 22a and 22b. This gave the title compounds as white powders.

(67) 23a: .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.88-1.02 (m, 9H), 1.02-1.40 (m, 7H), 1.55-1.97 (m, 6H), 2.01-2.10 (m, 1H), 2.38-2.52 (m, 1H), 2.88-3.00 (m, 1H), 3.77 (s, 3H), 3.98 (s, 3H), 4.08-4.20 (m, 1H), 4.22-4.40 (m, 3H). 6.03-6.18 (m, 1H), 6.86-6.99 (m, 1H), 7.08-7.20 (m, 1H), 7.23 (s, 1H), 7.40-7.43 (m, 1H), 7.45-7.70 (m, 3H), 8.02-8.20 (m, 3H). .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 9.0, 17.6, 18.2, 24.5, 25.3, 28.1, 28.8, 30.9, 35.4, 39.4, 49.6, 51.1, 54.7, 572, 58.0, 82.4, 98.5, 105.5, 114.5, 117.7, 122.7, 127.2, 127.3, 128.2, 129.0, 135.6, 136.4, 141.7, 149.9, 159.5, 161.2, 161.4, 164.0, 171.0, 171.7, 172.4. 23b: .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.9-1.20 (m, 9H), 1.21-1.53 (m, 7H), 1.55-1.93 (m, 6H), 2.05-2.20 (m, 1H), 2.41-2.50 (m, 1H), 2.96-3-05 (m, 1H), 3.77 (s, 3H), 4.00 (s, 3H), 4.05-4.40 (m, 4H), 6.05-6.18 (m, 1H), 6.90-6.95 (m, 1H), 7.05-7.22 (m, 2H), 7.50-7.65 (m, 4H), 8.01-8.16 (m, 3H).

Example 24

(68) ##STR00077##

(S)-2-{[((1R,4R) & (1S,4S))-2-{((S)-1-[((S)-Carboxy-cyclohexyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric acid (24)

(69) The tert.butyl ester 14 (13.4 mg, 0.017 mmol), TES (4.83 mg, 0.042 mmol), DCM (2 mL) and TFA (2 mL) were mixed n a round bottomed flask. One hour later the mixture was concentrated and purified by HPLC using 65% MeOH+0.2% TEA as mobile phase. This gave 24 (4.3 mg, 34%) as a slightly yellow syrup. After lyophilisation 24 was collected as a white powder.

(70) .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.91-0.99 (m, 9H), 1.00-1.28 (m, 4H), 1.65-1.78 (m, 9H), 1.92-1.95 (m, 1H), 2.00-2.05 (m, 1H), 2.93-3.01 (m, 1H), 3.75 (s, 3H), 3.97 (s, 3H), 4.10-4.40 (m, 4H), 6.05-6.15 (m, 1H), 6.88-6.94 (m, 1H), 7.05-7.10 (m, 2H), 7.41-7.43 (m, 1H), 7.44-7.55 (m, 2H), 8.62-8.68 (m, 1H), 8.69-8.79 (m, 1H), 7.97-8.05 (m, 2H). .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 9.2, 18.5, 25.5, [29.0 & 29.2], [30.0 & 30.5], 35.3, 37.7, 39.7, 46.2, 50.0, [51.4 & 51.5], 53.6, 55.1, 57.1, 58.4, 83.1, 98.9, 104.9, 114.6, 118.3, 123.0, 123.4, 127.5, 128.4, 128.5, 129.7, 135.0, 142.1, 145.7, 1462, 159.2, 161.9, 164.3, 171.5, 171.9, 172.2. MALDI-TOF m/z 791.27 [(M+K).sup.+ calcd for C.sub.42H.sub.48KN.sub.4O.sub.9.sup.+ 791.31].

Example 25

(71) ##STR00078##

(S)-2-{[((3R,5R) & (3S,5S))-5-((S)-1-Carboxy-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarbonyl]-amino}-3-methyl-butyric acid methyl ester (25)

(72) Compound 25 (8.0 mg, 60%) was prepared from 18 (13.8 mg, 0.022 mmol) according to the method for the preparation of 24 which gave the title compound as a white powder.

(73) .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.83-1.02 (m, 9H), 1.88-1.80 (m, 1H), 1.82-2.02 (m, 1H), 2.10-2.22 (m, 1H), 2.40-2.60 (m, 1H), 2.81-2.95 (m, 1H), 3.75 (s, 3H), 4.00 (s, 3H), 4.18-4.22 (m, 1H), 4.27-4.40 (m, 2H), 6.05-6.12 (m, 1H), 6.99-7.02 (m, 1H), 7.16-7.21 (m, 1H), 7.38 (s, 1H), 7.40-7.43 (m, 1H), 7.48-7.61 (m, 3H), 7.98-8.12 (m, 3H).

Example 26

(74) ##STR00079##

(S)-2-{[((1R,4R) &(1 S,4S))-2-{(S)-1-[(2,5-Dimethoxy-phenyl)-ethyl-carbamoyl]-2-methyl-propylcarbamoyl}4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric add (26)

(75) Compound 26 (5.7 mg, 36%) was prepared from 17 (16.7 mg, 0.021 mmol) according to the method for the preparation of 24 which gave the title compound as a white powder.

(76) .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.75-0.81 (m, 6H), 0.82-0.98 (m, 3H), 1.00-1.10 (m, 3H), 1.60-2.00 (m, 3H), 2.40-2.56 (m, 1H), 2.80-2.88 (m, 1H), 3.18-3.24 (m, 1H), 3.40-3.48 (m, 1H), [3.67-3.80 (m, 6H)], 3.97 (s, 3H), 4.10-4.20 (m, 1H), 4.21-4.40 (m, 2H), 6.02-8.17 (m, 1H), 6.75-6.82 (m, 1H), 6.84-7.01 (m, 3H), 7.10-720 (m, 1H), 7.30-7.37 (m, 1H), 7.40-7.43 (m, 1H), 7.50-7.60 (m, 3H), 8.00-8.17 (m, 3H). .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 9.6, [11.8 & 12.0], [17.2 & 17.4], 18.9, 25.0, 32.3, 35.7, 43.3, 44.2, [50.3 & 50.5], [54.5 & 54.8 & 54.9 & 55.0], [55.1 & 55.2 & 55.3 & 58.0], 58.7, 83.6, 99.3, 105.5, [112.5 & 112.7], 114.3, [15.1 & 115.2], 115.7, 116.1, 118.4, [123.3 & 123.4], 125.2, [128.0 & 128.1, 128.8, 129.1, 129.8, [135.1 & 135.3], 139.2, (143.3 & 144.4], 149.2, [149.6 & 149.9], 153.8, 159.9, 162.4, [163.9 & 164.5], 172.1, 172.8, [173.6 & 173.7]. MALDI-TOF m/z 775.30 [(M+Na).sup.+ calcd for C.sub.42H.sub.48N.sub.4NaO.sub.9.sup.+ 775.33].

Example 27

(77) ##STR00080##

(S)-2-{[((R,4R) &(1 S,4S))-2-{(S-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-butyric acid (27)

(78) Compound 27 (6.0 mg, 72%) was prepared from 18 (8.6 mg, 0.011 mmol) according to the method for the preparation of 24. Purification by HPLC (60% methanol+0.2% TEA) gave the title compound as a white powder.

(79) .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.88-0.95 (m, 3H), 0.98 (s, 9H), 0.97-1.24 (m, 4H), 1.57-1.62 (m, 3H), 1.58-1.78 (m, 4H), 1.79-1.99 (m, 1H), 2.35-2.44 (m, 2H), 2.85-2.98 (m, 1H), [(3.67 & 3.69) 8, 3H], 3.94 (s, 3H), 4.10-4.20 (m, 1H), 4.30-4.40 (m, 3H), 6.00-6.09 (m, 1H), [6.80-6.82 (m, 0.5H)] [6.85-6.87 (m, 0.5H)], 7.05-7.19 (m, 2H), 7.38-7.55 (m, 4H), 7.95-8.07 (m, 3H). .sup.13C-NMR (75.5 MHz, CD.sub.3OD): [9.1 & 9.2], [24.7 & 24.9], [25.4 & 25.5], [25.9 & 26.0], [28.3 & 28.4], 28.9, [34.8 & 34.9], [35.6 & 35.9], [39.6 & 39.7], [49.9 & 50.13, [51.4 & 51.2], [53.9 & 54.0] 55.0. 157.2 & 57.4], 60.0, [82.1 & 82.5], 98.6, 106.2, 114.7, 117.8, 122.7, 127.5, 127.7, [128.4 & 128.5], 129.1, 135.3, 136.3, 141.6, 142.0, 150.5, 159.8, [161.0 & 161.3] [164.0 & 164.1], [171.6 & 171.9], [1722 & 172.3], [173.0 & 173.2]. MALDI-TOF m/z 779.43 [(M+Na).sup.+ calcd for C.sub.42H.sub.52N.sub.4NaO.sub.9.sup.+ 779.36].

Example 28

(80) ##STR00081##

(S)-2-{[(1R,4R)-2-{(S)-1-{((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl}-2-methyl-propylcarbamoyl}-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-pentanoic acid tert-butyl ester (28)

(81) The tert.butyl ester 19a (7.6 mg, 0.0094 mmol) and TES (2.4 mg, 0.021 mmol) were dissolved in DCM (1 mL) and the mixture was cooled in an ice-bath. TFA (1 mL) was added. After two hours the mixture was concentrated and purified on HPLC using 60% MeOH+0.2% TEA as mobile phase. This gave 28 (6.1 mg, 86%) as a slightly yellow syrup. After lyophilisation the title compound was collected as white powder. .sup.1H-NMR (300 MHz, CD.sub.3OD+CDCl3 (1:1)): 0.90-1.00 (m, 9H), 1.00-1.30 (m, 7H), 1.50-1.90 (m, 8H), 2.00-2.10 (m, 1H), 2.40-2.50 (m, 1H), 2.85-2.98 (m, 1H), 3.65-3.72 (s, 3H), 3.99 (s, 3H), 4.15-4.22 (m, 1H), 4.24-4.35 (m, 2H), 4.38-4.44 (m, 1H), 6.10-6.20 (m, 1H), 6.95-6.96 (m, 1H), 7.16-7.23 (m, 1H), 7.31 (s, 1H), 7.42 (d, J=2.47 Hz, 1H), 7.53-7.72 (m, 3H), 7.97-8.16 (m, 3H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD+CDCl.sub.3 1:1): 13.5, 18.3, 19.0, 26.0, 29.0, 29.7, 31.0, 34.1, 35.8, 40.2, 51.9, 55.9, 57.7, 58.9, 63.5, 68.4, 84.0, 99.6, 104.8, 105.7, 115.1, 119.0, 123.7, 128.1, 128.9, 129.1, 130.4, 131.3, 135.3, 138.0, 142.9, 159.5, 162.8, 164.8, 172.2, 172.2, 172.4

Example 29

(82) ##STR00082##

(S)-2-{[(1 S,4S)-2-{(S)-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl}-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-pentanoic acid tert-butyl ester (29)

(83) Compound 29 (1.3 mg, 28%) was prepared from 19b (5.3 mg, 0.065 mmol) according to the method for the preparation of 28. This gave the title compound as a white powder.

(84) .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.85-1.00 (m, 9H), 1.00-1.23 (m, 7H), 1.50-1.78 (m, 8H), 2.05-2.23 (m, 1H), 2.50-2.66 (m, 1H), 2.70-2.85 (m, 1H), 3.69 (s, 3H), 3.92 (s, 3H), 4.02-4.16 (m, 1H), 4.20-4.25 (m, 1H), 4.35-4.40 (m, 2H), 6.09 (m, 1H), 7.00 (s, 1H), 7.12-7.18 (dd, J=2.47, 2.19 Hz, 1H), 7.30 (s, 1H), 7.40 (d, J=2.42 Hz, 1H), 7.48-7.74 (m, 3H), 8.03-8.10 (m, 3H); .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 11.7, 16.5, 17.0, 24.4, 27.2, 27.9, 29.0, 29.1 37.5, 41.8, 49.7, 50.5, 53.3, 56.3, 63.5, 66.5, 81.0, 100.3, 101.0, 105.7, 113.6, 121.6, 128.3, 127.1, 127.9, 130.1, 131.4, 135.6, 138.7, 141.1, 150.4, 160.2, 160.5, 165.3, 173.0, 173.6, 173.7

Example 30

(85) ##STR00083##

(1R,2S)-1-{[(1R,4R)-2-{(S)-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid (30a) and 1R,2S)-1-{[(1 S,4S)-2-{(S)-1-[((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino}-2-vinyl-cyclopropane-carboxylic acid (30b)

(86) Compound 30a (6.3 mg, 49%) and compound 30b (5.6 mg, 43%) were synthesized from 21 (13.8 mg, 0.0016 mmol) according to the method of the preparation of 22a and 22b. 30a and 30b: White powder.

(87) 30a: .sup.1H-NMR (300 MHz, CD.sub.3OD): 1.02 (s, 9H), 1.03-1.43 (m, 5H), 1.61-1.95 (m, 8H), 2.11-2.21 (m, 1H), 2.43-2.58 (m, 1H), 2.97-3.04 (m, 1H), 3.78 (s, 3H), 4.01 (s, 3H), 4.02-4.17 (m, 1H), 4.25-4.40 (m, 2H), 5.10-5-20 (m, 1H), 5.27-5.40 (m, 1H), 6.77-6.94 (m, 1H), 6.10-6.20 (m, 1H), 6.97 (s, 1H), 7.18 (dd, J=2.5, 92 Hz, 1H), 7.22 (s, 1H), 7.46 (d, J=2.5 Hz, 1H), 7.52-7.65 (m, 3H), 8.00-8.18 (m, 3H). .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 13.5, 25.3, 25.7, 28.3, 28.7, 29.0, 32.8, 34.6, 35.3, 39.3, 49.7, 51.1, 54.6, 57.2, 59.8, 82.1, 98.4, 105.8, 114.5, 116.3, 117.6, 122.6, 127.2, 128.1, 128.2, 128.8, 130.2, 133.7, 136.0, 139.5, 141.5, 150.3, 159.7, 161.0, 1612, 163.4, 171.6, 172.5. MALDI-TOF m/z 803.56 [(M+Na).sup.+ calcd for C.sub.44H.sub.52N.sub.4NaO.sub.9.sup.+ 803.36]. 30b: .sup.1H-NMR (300 MHz, CD.sub.3OD): 1.03 (s, 9H), 1.04-1.42 (m, 5H), 2.60-2.90 (m, 8H), 2.17-2.22 (m, 1H), 2.40-2.55 (m, 1H), 2.96-3.10 (m, 1H), 3.77 (s, 3H), 4.01 (s, 3H), 4.05-4.16 (m, 1H), 4.30-4.40 (m, 2H), 5.15-5.20 (m, 1H), 5.25-5.40 (m, 1H), 5.78-5.95 (m, 1H), 6.10-6.20 (m, 1H), 6.98 (s, 1H), 7.17 (dd, J=2.5, 9.1 Hz, 1H), 7.28 (s, 1H), 7.46 (d, J=2.5 Hz, 1H), 7.50-7.65 (m, 3H), 8.03-8.28 (m, 3H). .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 13.7, 26.0, 26.3, 28.8, 29.4, 29.6, 34.0, 35.2, 35.8, 40.1, 50.6, 51.7, 55.3, 57.8, 80.6, 83.0, 99.1, 106.3, 115.2, 117.0, 118.3, 1232, 127.9, 128.0, 128.8, 129.6, 130.6, 134.4, 136.1, 140.0, 142.5, 150.8, 160.3, 161.8, 162.0, 165.7, 172.3, 173.0

Example 31

(88) ##STR00084##

trans-(3R,4R)-Bis(methoxycarbonyl)cyclopentanol (31)

(89) Sodium borohydride (1.11 g, 0.029 mol) was added to a stirred solution of (1R,2S)-4-oxo-cyclopentane 1,2-dicarboxylic add dimethyl ester (4.88 g, 0.0244 mol) in methanol (300 mL) at 0 C. After 1 h the reaction was quenched with 90 mL brine, concentrated and extracted with ethyl acetate. The organic phases were pooled, dried, filtered and concentrated. The crude product was purified by flash column chromatography (toluene/ethyl acetate 1:1) to give 31 (3.73 g, 76%) as a yellow oil.

Example 32

(90) ##STR00085##

3-Oxo-2-oxa-bicyclo[22.2.1]heptane-6-carboxylic acid (32)

(91) Sodium hydroxide (1M, 74 ml, 0.074 mol) was added to a stirred solution of 31 (3.73 g, 0.018 mol) in methanol (105 mL) at room temperature. After 4 h, the reaction mixture was neutralized with 3M HCl, evaporated and co-evaporated with toluene several times. Pyridine (75 mL) and Ac.sub.2O (53 mL) were added and the reaction mixture was allowed to shake overnight at room temperature. The mixture was then co-evaporated with toluene and purified by flash column chromatography (ethyl acetate+1% acetic acid) to give 32 (2.51 g, 88%) as a yellow oil.

Example 33

(92) ##STR00086##

3-Ox-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid tert-butyl ester (33)

(93) DMAP (14 mg, 0.115 mmol) and Boc.sub.2O (252 mg, 1.44 mmol) was added to a stirred solution of 32 (180 mg, 1.15 mmol) in 2 mL CH.sub.2Cl.sub.2 under inert argon atmosphere at 0 C. The reaction was allowed to warm to room temperature and was stirred overnight. The reaction mixture was concentrated and the crude product was purified by flash column chromatography (toluene/ethyl acetate gradient 15:1, 9:1, 6:1, 4:1, 2:1) to give 33 (124 mg, 51%) as white crystals.

(94) .sup.1H-NMR (300 MHz, CD.sub.3OD) 1.45 (s, 9H), 1.90 (d, J=11.0 Hz, 1H), 2.10-2.19 (m, 3H), 2.76-2.83 (m, 1H), 3.10 (s, 1H), 4.99 (s, 1H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD) 27.1, 33.0, 37.7, 40.8, 48.1, 81.1, 81.6, 172.0, 177.7.

Example 34

(95) ##STR00087##

(1R,2R,4S)-2-((1R,2S)-1-Ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-hydroxy-cyclopentanecarboxylic acid tort-butyl ester (34)

(96) Compound 33 (56 mg, 0.264 mmol) was dissolved in dioxane/water 1:1 (5 mL) and the mixture was cooled to 0 C. 1 M lithium hydroxide (0.62 mL, 0.520 mmol) was added and the mixture was stirred at 0 C. for 45 minutes, after which the mixture was neutralized with 1M hydrochloric acid and evaporated and coevaporated with toluene. The residue was dissolved in DMF (5 mL) and (1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester hydrochloride (60 mg, 0.313 mmol) and diisopropylethylamine (DIEA) (138 L, 0.792 mmol) were added and the solution was cooled to 0 C. HATU (120 mg, 0.316 mmol) was added and the mixture was stirred for 0.5 h at 0 C. and for an additional 2 h at room temperature. The mixture was then evaporated and extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification by flash column chromatography (toluene/EtOAc 1:1) provided compound 34 (86 mg, 89%) as a colorless oil.

Example 35

(97) ##STR00088##

(1R,2R,4R)-2-((1R,2S)-1-Ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarboxylic acid tert-butyl ester (35)

(98) Compound 34 (73 mg, 0.199 mmol) was dissolved in dry THF (4 mL) and 2-phenyl-7-methoxy-4-quinolinol (88 mg, 0.342 mmol) and triphenylphosphine (141 mg, 0.538 mmol) were added. The mixture was cooled to 0 C. and DIAD (0.567 mmol) dissolved in 1 mL THF was added dropwise. The mixture was stirred for 48 h at room temperature. The solvent was evaporated and the crude product was purified by flash column chromatography gradient elution (toluene/EtOAc 9:1, 6:1, 4:1) to give compound 35 (81 mg, 68%).

Example 36

(99) ##STR00089##

Boc-L-ter-leucine-OH (38)

(100) Triethylamine (890 uL, 6.40 mmol) was added dropwise to a stirred solution of L-tert-leucine (300 mg, 2.29 mmol) and di-tert-butyl dicarbonate (599 mg, 2.74 mmol) in dioxane/water 1:1 (8 mL) and the solution was stirred overnight. The mixture was extracted with petroleum ether (2) and the aqueous phase was cooled to 0 C. and carefully acidified to pH 3 by slow addition of 4M NaHSO.sub.4.H.sub.2O. The acidified water phase was extracted with EtOAc (3) and the combined organic phases were washed with brine (2) and was then dried, filtered and concentrated to give compound 36 (522 mg, 99%) as a colorless powder. No further purification was needed. .sup.1H-NMR (300 MHz, CD.sub.3OD) 0.99 (s, 9H), 1.44 (s, 9H), 3.96 (s, 1H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD) 27.1, 28.7, 34.9, 68.0, 80.5, 157.8, 174.7.

Example 37

(101) ##STR00090##

((S)-Cyclohexyl-methylcarbamoyl-methy)-carbamic acid tert-butyl ester (37)

(102) Boc-Chg-OH (387 mg, 1.50 mmol) was coupled to methylamine hydrochloride (111 mg, 1.65 mmol) using the same HATU coupling conditions as in the synthesis of compound 34. The crude product was extracted with EtOAc, washed with brine and concentrated. Purification by flash column chromatography (EtOAc) provided compound 37 (307 mg, 76%) as a colorless solid.

(103) .sup.1H-NMR (300 MHz, CDCl.sub.3) 0.91-1.13 (m, 2H), 1.14-1.31 (m, 3H), 1.44 (s, 9H), 1.61-1.80 (m, 6H), 2.80 (d, J=4.7 Hz, 3H), 3.91 (dd, J=7.1, 9.1 Hz, 1H), 5.23 (b, 1H), 6.52 (be, 1H); .sup.13C-NMR (75.5 MHz, CDCl.sub.3) 25.9, 28.0, 26.1, 28.3, 28.5, 29.6, 40.5, 59.5, 79.7, 155.9, 172.4.

Example 38

(104) ##STR00091##

{(S)-1-[((S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propyl}-carbamic add tert-butyl ester (38)

(105) To a solution of compound 37 (98 mg, 0.362 mmol) in methylene chloride (3 mL) were added triethylsilane (115 mL, 0.742 mmol) and TFA (3 mL). The mixture was stirred for 2 h at room temperature and was then evaporated and coevaporated with toluene. The deprotected amine was dissolved in DMF (5 mL) and coupled to compound 36 (84 mg, 0.363 mmol) using the same HATU coupling conditions as in the synthesis of 34. The crude product was extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification by flash column chromatography (toluene/EtOAc 1:1) provided compound 38 (128 mg, 92%) as a colorless solid.

(106) .sup.1H-NMR (300 MHz, CDCl.sub.3) 0.99 (s, 9H), 1.02-1.30 (m, 5H), 1.44 (s, 9H), 1.58-1.77 (m, 4H), 1.78-1.89 (m, 2H), 2.79 (d, J=4.7 Hz, 3H), 4.11 (d, J=9.3 Hz, 1H), 4.33 (app. t, J, 8.5 Hz, 1H), 5.65 (b, 1H), 7.25 (b, 1H), 7.39 (b, 1H); .sup.13C-NMR (75.5 MHz, CDCl.sub.3) 25.9, 25.9, 26.0, 26.2, 26.8, 28.4, 29.0, 29.7, 34.5, 39.7, 58.4, 62.4, 79.4, 156.0, 171.4, 171.8.

Example 39

(107) ##STR00092##

(1R,2S)-1-{[(1R,2R,4S)-2-{(S)-1-[((S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-diethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid ethyl ester (39)

(108) To a solution of compound 35 (30 mg, 0.050 mmol) in methylene chloride (1.5 mL) were added triethylsilane (21 L, 0.132 mmol) and TFA (1.5 ml). The mixture was stirred for 2 h at room temperature and was then evaporated and coevaporated with toluene. The amine 38 (1.3 eq) was deprotected in the same manner as compound 35 and was then coupled to deprotected compound 35 using the same HATU coupling conditions as in the synthesis of 34. The crude product was extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification using HPLC (MeOH/water 9.1+0.2% triethylamine) provided compound 39 (30 mg, 74%) as a colorless sold.

(109) .sup.1H-NMR (300 MHz, CD.sub.3OD) 0.81-1.14 (m, 4H), 0.99 (s, overlapped, 9H), 1.21 (t, J 7.1 Hz, 3H), 1.35-1.51 (m, 4H), 1.52-1.65 (m, 3H), 1.66-1.72 (m, 2H), 2.03-2.20 (m, 2H), 2.24-2.39 (m, 1H), 2.46-2.56 (m, 1H), 2.66 (s, 3H), 2.72-2.85 (m, 1H), 3.39-3.48 (m, 2H), 3.90 (s, 3H), 4.03-4.15 (m, 3H), 4.44 (s, 1H), 5.09 (dd, J=1.9, 10.3 Hz, 1H), 5.19-5.27 (m, 1H), 5.25 (dd, overlapped, 1H), 5.79 (ddd, J=8.8, 10.3, 17.2 Hz, 1H), 8.99 (s, 1H), 7.07 (dd, J=2.5, 9.1, Hz, 1H), 7.29 (d, J=2.5 Hz, 1H), 7.43-7.52 (m, 3H), 7.86-7.98 (m, 2H), 8.05 (d, J=9.3 Hz, 1H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD) 14.7, 23.4, 28.0, 26.9, 27.1, 27.3, 30.1, 30.7, 35.0, 35.4, 38.3, 38.8, 40.9, 41.0, 47.9, 55.9, 59.6, 62.0, 62.4, 79.8, 99.9, 107.3, 116.4, 118.0, 119.1, 124.4, 128.9, 129.8, 130.5, 135.3, 141.3, 152.1, 161.1, 162.4, 163.0, 171.6, 172.5, 173.7, 175.2, 176.8. Maldi-TOF-spectrum: (M+H).sup.+ calcd: 810.4, found: 810.5; (M+Na).sup.+ calcd: 832.4, found: 832.4; (M+K).sup.+ calcd: 848.5, found: 848.4.

Example 40

(110) ##STR00093##

(1R,2S)-1-{[(1R,2R,4S)-2-{(S)-1-[((S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid (40)

(111) To a solution of compound 39 (20 mg, 0.025 mmol) in THF/MeOH/water 2:1:1 (2 mL) at 0 C. was added 1M LiOH (175 uL, 0.175 mmol) and the solution was allowed to attain room temperature and was stirred for 48 h. The solution was acidified to pH 3 with 1M HCl and was then evaporated and coevaporated with toluene. The crude product was purified by HPLC (MeOH/water 6:4+0.5% TFA followed by MeOH/water 4:1+0.2% TFA) to give compound 40 (13 mg, 67%) as a colorless solid. .sup.1H-NMR (300 MHz, CD.sub.3OD) 0.82-0.98 (m, 1H), 1.01 (s, 9H), 1.05-1.26 (m, 3H), 1.34-1.43 (m, 1H), 1.49-1.77 (m, 8H), 2.10-2.21 (m, 1H), 2.28-2.42 (m, 2H), 2.50-2.61 (m, 1H), 2.64 (s, 3H), 2.68-2.81 (m, 1H), 3.36-3.45 (m, 2H), 4.04-4.11 (m, 1H), 4.06 (s, overlapped, 3H), 4.27 (d, J=8.8 Hz, 1H), 5.10 (dd, J=1.8, 10.3 Hz, 1H), 5.28 (dd, J=1.8, 17.2 Hz, 1H), 5.59-5.68 (m, 1H), 5.82 (ddd, J=9.1, 10.3, 17.2 Hz, 1H), 7.44 (dd, J=2.5, 11.8 Hz, 1H), 7.50 (s, 1H), 7.53 (d, J=2.5 Hz, 1H), 7.69-7.78 (m, 3H), 8.02-8.07 (m, 2H), 8.39 (d, J=9.3 Hz, 1H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD) 23.5, 26.0, 26.9, 27.2, 27.3, 30.0, 30.7, 34.7, 35.3, 37.0, 38.7, 41.0, 41.3, 47.4, 56.9, 59.4, 62.7, 83.9, 100.4, 1022, 1162, 117.7, 121.7, 126.7, 129.8, 130.8, 133.4, 133.9, 135.6, 143.5, 158.0, 166.6, 168.6, 172.5, 173.4, 173.6, 175.4, 176.4. Maldi-TOF-spectrum: (M+H).sup.+ calcd: 782.4, found: 782.2; (M+Na).sup.+ calcd: 804.4, found: 804.2; (M+K).sup.+ calcd: 820.5, found: 820.2.

Example 41

(112) ##STR00094##

3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid meth ester (41)

(113) Compound 32 (1.014 g, 6.50 mmol) was dissolved in acetone (35 mL) before methyl Iodide (13.68 g, 96.4 mmol) and sliver(I)oxide (1.61 g, 6.95 mmol) were added. After stirring for 3 h the mixture was filtered through celite and the filtrate was evaporated before purification by flash column chromatography (toluene/ethyl acetate 4:1) was performed yielding the methyl ester 41 (702 mg, 64%) as white crystals. .sup.1H-NMR (300 MHz, CDCl.sub.3): 1.96 (d, J=10.7 Hz, 1H), 2.21-2.25 (m, 3H), 2.91-2.95 (m, 1H), 3.16 (s, 1H), 3.75 (s, 3H), 4.98 (app. s, 1H).

Example 42

(114) ##STR00095##

(1R,2R,4S)-2-((S)-1-tert-Butoxycarbonyl-butylcarbamoyl)-4-hydroxy-cyclopentanecarboxylic acid methyl ester (42)

(115) Compound 41 (263 mg, 1.55 mmol) and H-Nva-OtBu (420 mg, 2.42 mmol) were dissolved in dry THF (20 mL). DIEA (530 uL, 3.04 mmol) and 2-hydroxypyridine (260 mg, 2.73 mmol) were added and the mixture was refluxed for five days. The solvent was evaporated and the crude product was purified by flash column chromatography (toluene/EtOAc 1:2) to give 42 (510 mg, 96%).

Example 43

(116) ##STR00096##

(1R,2R,4R)-2-((S)-1-tert-Butoxycarbonyl-butylcarbamoyl)-4-(7-methoxy-2-phenyl quinolin-4-yloxy)-cyclopentanecarboxylic acid methyl eater (43)

(117) Compound 42 (249 mg, 0.725 mmol), 2-phenyl-7-methoxy-4-quinolinol (310 mg, 1.23 mmol) and PPh.sub.3 (580 mg, 2.21 mmol) were dissolved in dry THF and the temperature was lowered to 0 C. DIAD (435 uL 2.21 mmol) dissolved in 2 mL dry THF, was added to the mixture during five minutes. After two hours the temperature was raised to room temperature and the solution was stirred overnight. Evaporation and purification by flash column chromatography (toluene/EtOAc gradient 6:1 to 4:1) gave 43 (324 mg, 78%).

Example 44

(118) ##STR00097##

(S)-2-{[(1R,2R,4S)-2-{(S)-1-[((S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-pentanoic acid tert-butyl ester (44)

(119) Compound 43 (38 mg, 0.066 mmol) was dissolved in dioxane/water 1:1 (4 mL) and the solution was cooled to 0 C. and 1 M LiOH (132 ul, 0.132 mmol) was added. The temperature was raised to room temperature and the solution was stirred for 2 hours after which it was neutralized by addition of M HCl and evaporated and coevaporated with toluene. The residue and deprotected amine 38 (1.1 eq) was dissolved in DMF and coupled using the standard HATU coupling conditions as in the synthesis of compound 34. The crude product was extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification with HPLC (MeOH/water 9:1+0.2% TEA) provided compound 44 (44 mg, 81%) as a colorless solid.

(120) .sup.1H-NMR (CDCl.sub.3, 300 MHz) rotamers (5:1) 0.79 (t, J=7.3 Hz, 3H), 0.85-1.19 (m, 3H), 0.93 (s, overlapped, 9H), 1.20-1.35 (m, 2H), 1.39 (s, 1.5H), 1.43 (s, 7.5H), 1.54-1.79 (m, 6H), 2.06-2.28 (m, 3H), 2.39-2.51 (m, 2H), 2.66-2.78 (m, 1H), 2.74 (d, overlapped, J=4.7 Hz, 3H), 3.42-3.68 (m, 2H), 3.84 (s, 2.5H), 3.88 (s, 0.5H), 4.19 (t, J=8.9 Hz, 1H), 4.39-4.59 (m, 1H), 4.68 (d, J=9.6 Hz, 1H), 5.04-5.14 (m, 1H), 6.77 (s, 1H), 6.88-7.06 (m, 2H), 7.26-7.47 (m, 6H), 7.53 (b, 1H), 7.85-7.97 (m, 3H); .sup.13C-NMR (75.5 MHz, CDCl.sub.3) 13.7, 18.7, 25.6, 25.7, 26.0, 26.7, 28.0, 28.9, 29.7, 34.5, 34.7, 37.7, 38.0, 39.2, 46.6, 47.7, 52.7, 55.3, 58.5, 60.3, 77.9, 81.7, 98.0, 107.4, 115.0, 117.9, 122.8, 127.4, 128.6, 129.0, 140.2, 151.2, 158.9, 160.6, 161.1, 170.9, 171.6, 171.8, 172.7, 173.3. Maldi-TOF-spectrum: (M+H).sup.+ calcd: 828.5, found: 828.6; (M+Na).sup.+ calcd: 850.5, found: 850.6; (M+K).sup.+ calcd: 866.6, found: 866.6.

Example 45

(121) ##STR00098##

(S)-2-{[(1R,2R,4S)-2-{(S)-1-[((S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-pentanoic acid (45)

(122) Compound 44 (21 mg, 0.025 mmol) was dissolved in CH.sub.2Cl.sub.2 (1.5 mL) and triethylsilane (10 uL, 0.063 mmol) and TFA (1.5 mL) were added. The solution was stirred for 2 hours at room temperature after which the solvents were evaporated and co-evaporated with toluene to provide compound 45 (20 mg, 100%) as a colorless solid.

(123) .sup.1H-NMR (300 MHz, CD.sub.3OD) 0.93 (t, overlapped, 3H), 0.98 (s, 9H), 0.99-1.25 (m, 4H), 1.30-1.49 (m, 3H), 1.50-1.90 (m, 8H), 2.25-2.39 (m, 2H), 2.54-2.62 (m, 1H), 2.64 (s, 3H), 2.72-2.87 (m, 1H), 3.34-3.57 (m, 3H), 4.02-4.13 (m, 1H), 4.06 (s, overlapped, 3H), 427-4.36 (m, 1H), 4.37-4.47 (m, 1H), 5.57-5.66 (m, 1H), 7.45 (dd, J=2.3, 9.2 Hz, 1H), 7.48 (s, 1H), 7.54 (d, J=2.2 Hz, 1H), 7.69-7.79 (m, 3H), 8.01-8.07 (m, 2H), 8.42 (d, J=9.3 Hz, 1H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD) 14.0, 20.2, 26.0, 26.9, 27.2, 30.1, 30.7, 34.6, 35.3, 37.2, 39.1, 41.2, 47.7, 53.7, 56.9, 59.4, 59.5, 62.5, 83.7, 100.4, 101.3, 102.2, 116.2, 121.7, 126.7, 129.8, 130.8, 133.3, 133.9, 143.5, 157.9, 166.6, 168.5, 172.5, 173.6, 175.3, 175.4, 175.5.

(124) Maldi-TOF-spectrum: (M+H).sup.+ calcd: 772.4, found: 772.6; (M+Na).sup.+ calcd: 794.4, found: 794.6; (M+K).sup.+ calcd: 810.5, found: 810.6.

Example 46

(125) ##STR00099##

Hept-6-enal (46)

(126) To a solution of hept-6-en-1-ol (1 mL, 7.44 mmol) and N-methylmorpholine N-oxide (1.308 g, 11.17 mmol) in DCM (17 mL) was added ground molecular sieves (3.5 g, 4 ). The mixture was stirred for 10 min at room temperature under nitrogen atmosphere before tetrapropylammonium perruthenate (TPAP) (131 mg, 0.37 mmol) was added. After stirring for additional 2.5 h the solution was filtered through celite. The solvent was then carefully evaporated and the remaining liquid was purified by flash column chromatography (DCM) to give the volatile aldehyde 46 (620 mg, 74%) as an ol.

Example 47

(127) ##STR00100##

N-Hept-6-en-(E)-ylidene-hydrazinecarboxylic acid tert-butyl ester (47)

(128) To a solution of 46 (68 mg, 0.610 mmol) and tart-butyl carbazate (81 mg, 0.613 mmol) in MeOH (5 mL) was added ground molecular sieves (115 mg, 3 ). The mixture was stirred for 3 h after which it was filtered through celite and evaporated. The residue was dissolved in dry THF (3 mL) and AcOH (3 mL). NaBH.sub.3CN (95 mg, 1.51 mmol) was added and the solution was stirred over night. The reaction mixture was diluted with saturated NaHCO.sub.3 solution (6 mL) and EtOAc (6 mL). The organic phase was washed with brine, saturated NaHCO.sub.3, brine, dried over MgSO.sub.4 and evaporated. The cyanoborane adduct was hydrolyzed by treatment with MeOH (3 mL) and 2 M NaOH (1.9 mL). The mixture was stirred for 2 h and the MeOH was evaporated. H.sub.2O (5 mL) and DCM (5 mL) were added and the water phase was extracted three times with DCM. The combined organic phases were dried and evaporated. Purification by flash column chromatography (toluene/ethyl acetate 9:1 with 1% triethylamine and toluene/ethyl acetate 6:1 with 1% triethylamine) provided 47 (85 mg, 61%) as an oil.

Example 48

(129) ##STR00101##

(1R,2)-1-{[(1R,2R,4R)-2-(N-tert-Butoxycarbonyl-N-hept-6-enyl-hydrazinocarbonyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid ethyl ester (48)

(130) Scaffold molecule 35 (135 mg, 0.225 mmol) and triethylsilane (71 L, 0.447 mmol) was dissolved in DCM (2 mL) after which trifluoroacetic acid (TFA) (2 mL) was added. The mixture was stirred for 2 h and thereafter co-evaporated with toluene in order to remove the TFA. The residue was dissolved in DMF (3 mL) and 47 (60 mg, 0.263 mmol) and DIEA (118 L, 0.677 mmol) were added. The temperature was lowered to 0 C. and the coupling reagent O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (94 mg, 0.247 mmol) was added. The cold solution was allowed to stir for half an hour and then for additional 16 h in room temperature. The solvent was removed by heating the reaction flask in a water bath under diminished pressure. The residue was thereafter dissolved in ethyl acetate and the organic phase was washed three times with brine, dried, filtered and evaporated. Purification by HPLC (MeOH/H.sub.2O 90.10 with 02% triethylamine) gave 48 (140 mg, 82%) as an oil.

(131) .sup.1H-NMR (300 MHz, CDCl.sub.3, 40 C.): 1.22 (t, J=7.1 Hz, 3H), 1.28-1.42 (m, 6H), 1.46 (s, 9H), 1.52-1.62 (m, 2H), 1.82-1.91 (m, 1H), 1.96-2.16 (m, 3H), 2.18-2.34 (m, 2H), 2.42-2.56 (m, 1H), 2.58-2.72 (m, 1H), 3.42 (app. bs, 3H), 3.66-3.84 (m, 1H), 3.92 (s, 3H), 4.15 (q, J=7.1 Hz, 2H), 4.88-5.02 (m, 2H), 5.07-5.18 (m, 2H), 5.20-5.32 (m, 1H), 5.63-5.84 (m, 2H), 6.62 (bs, 1H), 6.94 (s, 1H), 7.09 (dd, J=2.6, 9.2 Hz, 1H), 7.36-7.51 (m, 4H), 7.99-8.10 (m, 3H); .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 14.3, 23.0, 26.4, 26.6, 28.3, 28.6, 33.2, 33.5, 35.6, 37.6, 40.6, 44.7, 47.1, 48.6, 55.5, 61.5, 81.9, 98.4, 107.9, 114.5, 115.6, 118.1, 123.2, 127.6, 128.3, 128.7, 129.1, 133.5, 138.7, 140.7, 151.5, 154.5, 159.2, 160.9, 161.5, 170.5, 174.2, 176.3.

Example 49

(132) ##STR00102##

(Z)-(1R,4R,6S,16R,18R)-14-tert-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid ethyl ester (49)

(133) A solution of 48 (158 mg, 0.209 mmol) in dry DCM (25 mL) was bubbled with argon for 5 min. To the stirred solution under argon atmosphere was then added a solution of Hoveyda-Grubbs catalyst 2.sup.nd generation (11 mg, 0.018 mmol) in dry DCM (5 mL). The mixture was stirred at reflux under argon atmosphere for 16 h. The solvent was evaporated and purification by HPLC (MeOH/H.sub.2O 90:10 with 0.2% triethylamine) yielded 49 (107 mg, 70%) as a colorless solid.

(134) .sup.1H-NMR (300 MHz, CD.sub.3OD): 1.03-1.22 (m, 1H), 1.28 (t, J=7.1 Hz, 3H), 1.32-1.44 (m, 4H), 1.49 (s, 9H), 1.55-1.73 (m, 2H), 1.81-1.91 (m, 1H), 2.04-2.28 (m, 3H), 2.30-2.52 (m, 3H), 2.53-2.70 (m, 1H), 2.86-3.00 (m, 1H), 3.34-3.44 (m, 1H), 3.48-3.62 (m, 1H), 3.95 (s, 3H), 4.19 (q, J=7.1 Hz, 2H), 4.32-4.48 (m, 1H), 5.20-5.33 (m, 1H), 5.34 (bs, 1H), 5.58-5.70 (m, 1H), 7.10 (s, 1H), 7.14 (dd, J=2.5, 9.1 Hz, 1H), 7.39 (d, J=2.5 Hz, 1H), 7.45-7.55 (m, 3H), 8.00 (d, J=8.0 Hz, 2H), 8.17 (d, J=9.3 Hz, 1H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 14.6, 23.4, 27.5, 27.7, 28.0, 28.5, 30.7, 36.1, 38.1, 42.5, 45.8, 56.0, 62.7, 79.9, 82.8, 100.2, 107.4, 116.8, 119.1, 124.5, 126.5, 128.9, 129.8, 130.5, 135.8, 141.5, 152.2, 156.4, 161.3, 162.5, 163.1, 171.9, 175.8, 179.0. MALDI-TOF-spectrum: (M+H).sup.+ calcd: 727.4, found: 727.5.

Example 50

(135) ##STR00103##

(Z)-(1R,4R,6S,16R,18R)-14-tert-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid (50)

(136) To a solution of 49 (27 mg, 0.037 mmol) in THF/MeOH/H.sub.2O 2:1:1 (5 mL) was added 1 M LiOH (300 L, 0.300 mmol). The solution was stirred for 24 h at room temperature and finally for one hour at reflux. After acidification to pH 3-4 with 1 M HCl and evaporation the residue was purified by HPLC (MeOH/H.sub.2O 80:20 and MeOH/H.sub.2O 90:10) providing 50 (12 mg, 46%) as a colorless sold.

(137) .sup.1H-NMR (300 MHz, CD.sub.3OD): 1.06-1.24 (m, 1H), 126-1.42 (m, 3H), 1.48 (s, 9H), 1.52-1.73 (m, 3H), 1.80-1.90 (m, 1H), 2.02-2.15 (m, 1H), 2.15-2.40 (m, 4H), 2.43-2.54 (m, 1H), 2.54-2.68 (m, 1H), 2.88-3.00 (m, 1H), 3.35-3.48 (m, 1H), 3.49-3.66 (m, 1H), 3.96 (s, 3H), 4.32-4.48 (m, 1H), 5.25-5.42 (m, 2H), 5.56-5.88 (m, 1H), 7.14 (s, 1H), 7.17 (dd, J=2.5, 9.1 Hz, 1H), 7.40 (d, J=2.2 Hz, 1H), 7.46-7.58 (m, 3H), 8.00 (d, J=8.0 Hz, 2H), 8.19 (d, J=9.1 Hz, 1H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 23.6, 26.8, 27.8, 28.3, 28.5, 30.5, 35.8, 38.1, 43.0, 45.5, 56.0, 802, 82.7, 100.4, 106.9, 116.6, 1192, 124.7, 127.4, 129.0, 129.8, 130.7, 134.8, 140.9, 151.6, 156.5, 161.1, 163.0, 163.4, 173.8, 175.7, 179.3.

Example 51

(138) ##STR00104##

((S)-1-Cyclopentylcarbamoyl-2,2-dimethyl-propyl)-carbamic acid tert-butyl ester (51)

(139) To a cold solution of 36 (133 mg, 0.575 mmol), cyclopentylamine (64 L, 0.648 mmol) and DIEA (301 L, 1.73 mmol) in DMF (3 mL) was added the coupling reagent HATU (240 mg, 0.631 mmol). The mixture was stirred for half an hour and for additional two hours at room temperature. The solvent was removed by heating the reaction flask in a water bath under diminished pressure and the residue was dissolved in ethyl acetate, after which the organic phase was washed three times with brine, dried, filtered and evaporated. Purification by flash column chromatography (toluene/ethyl acetate 4:1) provided 51 (140 mg, 82%) as colorless crystals.

(140) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.95 (s, 9H), 1.28-1.48 (m, overlapped, 2H), 1.40 (s, 9H), 1.49-1.71 (m, 4H), 1.86-2.01 (m, 2H), 3.76 (b, 1H), 4.09-4.23 (m, 1H), 5.32 (b, 1H), 5.91 (b, 1H); .sup.13C-NMR (75.6 MHz, CDCl.sub.3): 23.6, 23.7, 26.5, 28.3, 32.6, 33.1, 34.5, 51.0, 62.2, 79.4, 155.9, 170.3.

Example 52

(141) ##STR00105##

(1R,2S)-1-{[(1R,2R,4S)-2-((S)-1-Cyclopentylcarbamoyl-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino)}-2-vinyl-cyclopropanecarboxylic acid ethyl ester (52)

(142) Compound 51 (298 mg, 0.048 mmol) and 35 (16 mg, 0.054 mmol) was deprotected and coupled according to the method for the preparation of 39. Purification by HPLC (MeOH/H.sub.2O 90:10 with 0.2% triethylamine) gave 52 (22 mg, 63%) as a colorless solid.

(143) .sup.1H-NMR (CDCl.sub.3, 300 MHz): 0.97 (s, 9H), 1.21 (t, J=7.1 Hz, 3H), 1.26-1.37 (m, 1H), 1.38-1.46 (m, 2H), 1.48-1.58 (m, 4H), 1.78-1.85 (m, 1H), 1.86-2.02 (m, 3H), 2.03-2.19 (m, 1H), 2.28-2.40 (m, 2H), 2.41-2.54 (m, 1H), 2.64-2.78 (m, 1H), 3.10-3.24 (m, 1H), 3.30-3.44 (m, 1H), 3.95 (s, 3H), 4.04-4.21 (m, 3H), 5.12 (dd, J=1.7, 10.3 Hz, 1H), 5.14-5.22 (m, 1H), 5.28 (dd, J=1.7, 17.0 Hz, 1H), 5.59 (b, 1H), 5.75 (ddd, J=8.8, 10.3, 17.0 Hz, 1H), 6.66-8.82 (m, 2H), 6.99 (s, 1H), 7.09 (dd, J=2.5, 9.1 Hz, 1H), 7.41-7.55 (m, 4H), 7.99-8.09 (m, 3H); .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 14.3, 22.9, 23.6, 23.6, 26.7, 32.7, 332, 33.7, 34.8, 35.9, 36.6, 40.2, 46.4, 47.5, 51.3, 55.5, 61.1, 61.4, 78.0, 98.4, 107.1, 115.2, 117.9, 118.2, 123.1, 127.6, 128.8, 129.3, 133.5, 159.1, 161.4, 169.4, 189.9, 173.1, 174.0. MALDI-TOF-spectrum: (M+H).sup.+ calcd: 725.4, found: 725.6; (M+Na).sup.+ calcd: 747.4, found: 747.6; (M+K).sup.+ calcd: 763.3, found: 763.5.

Example 53

(144) ##STR00106##

(1R,2S)-1-{[(1R,2R,4S)-2-((S)-1-Cyclopentylcarbamoyl-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid (53)

(145) To a solution of 52 (14 mg, 0.019 mmol) in dioxane/HO 1:1: (4 mL) was added 1 M LiOH (115 L, 0.115 mmol). The solution was stirred for 24 h at room temperature. Thereafter an additional portion of LiOH (75 uL, 0.075 mmol) was added and the solution was stirred for another 24 h. After acidification to approximately pH 3 with 1 M HCl and co-evaporation with toluene the residue was purified by HPLC (MeOH/H.sub.2O 70:30 with 02% TFA) yielding 53 (8 mg, 60%) as a colorless solid.

(146) .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.98 (s, 9H), 1.28-1.48 (m, 3H), 1.49-1.76 (m, 5H), 1.78-1.94 (m, 2H), 2.10-2.24 (m, 1H), 2.26-2.45 (m, 2H), 2.50-2.62 (m, 1H), 2.66-2.79 (m, 1H), 3.35-3.48 (m, 2H), 3.94-4.03 (m, 1H), 4.06 (s, 3H), 4.16-4.24 (m, 1H), 5.10 (dd, J=1.8, 10.3 Hz, 1H), 5.29 (dd, J=1.8, 17.2 Hz, 1H), 5.62 (b, 1H), 5.82 (ddd, J=9.1, 10.3, 17.2 Hz, 1H), 7.43 (dd, J=2.5, 9.3 Hz, 1H), 7.50 (s, 1H), 7.50-7.69 (dd, overlapped, 1H), 7.67-7.80 (m, 3H), 8.01-8.11 (m, 2H), 8.39 (d, J=9.3 Hz, 1H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 24.7, 24.7, 27.3, 33.1, 33.6, 34.7, 35.4, 36.9, 38.7, 41.0, 47.4, 52.3, 56.9, 62.3, 83.9, 100.4, 102.3, 116.2, 117.7, 121.6, 126.7, 129.8, 130.8, 133.4, 133.8, 135.6, 143.5, 158.0, 166.5, 168.6, 171.9, 173.4, 175.2, 176.4. MALDI-TOF-spectrum: (M+H).sup.+ calcd: 697.4, found: 897.3; (M+Na).sup.+ calcd: 718.7, found: 719.3; (M+K).sup.+ calcd: 735.3, found: 735.3.

Example 54

(147) ##STR00107##

(S)-tert-Butoxycarbonylamino-cyclohexyl-acetic add methyl ester (54)

(148) To a solution of Boc-Chg-OH (53 mg, 0206 mmol) in acetone (3 mL) were added methyl iodide (195 L, 3.1 mmol) and sliver (I) oxide (53 mg, 0.229 mmol). The mixture was allowed to stir over night in a reaction flask that was covered with aluminium foil Thereafter the solution was filtered through celite and evaporated. Purification by flash column chromatography (toluene/ethyl acetate 15:1) provided methyl ester 54 (56 mg, 100%) as a colorless oil.

(149) .sup.1H-NMR (300 MHz, CDCl.sub.3): 1.00-1.34 (m, 5H), 1.44 (s, 9H), 1.54-1.82 (m, 6H), 3.73 (s, 3H), 4.20 (dd, J=2.8, 5.0 Hz, 1H), 5.05 (bs, 1H); .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 26.0, 28.2, 28.3, 29.5, 41.1, 52.0, 58.3, 79.7, 155.6, 172.9.

Example 55

(150) ##STR00108##

(S)((S)-2-Benzyloxycarbonylamino-3-methy-butyrylamino)-cyclohexyl-acetic acid methyl ester (55)

(151) Compound 54 (93 mg, 0.343 mmol) was deprotected and coupled to Z-Val-OH (95 mg, 0.378 mmol according to the method for the preparation of 39. Flash column chromatography (toluene/ethyl acetate 4:1) gave 55 (131 mg, 94%) as a colorless solid.

(152) .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.92-1.30 (m, 11H), 1.54-1.88 (m, 6H), 2.02-2.18 (m, 1H), 3.72 (s, 3H), 4.05-4.18 (m, 1H), 4.52 (dd, J=3.0, 5.5 Hz, 1H), 5.12 (s, 2H), 5.49 (bs, 1H), 6.52 (bs, 1H), 7.34 (s, 5H); .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 17.8, 19.0, 25.8, 28.2, 29.3, 31.2, 40.5, 51.9, 56.8, 60.0, 88.8, 127.7, 127.9, 128.1, 128.3, 136.2, 156.3, 171.3, 172.2.

Example 56

(153) ##STR00109##

(S)-2-{[(1R,2R,4S)-2-{(S)-1-[((S)-Cyclohexyl-ethoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl}-4(7-methoxy-2-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-pentanol acid tert-butyl ester (56)

(154) To a solution of 55 (40 mg, 0.099 mmol) in ethanol (95%) (7.5 mL) was added palladium on active carbon (10%, 40 mg) and the mixture was hydrogenated under pressure at room temperature for 2 h. The mixture was filtered through celite and evaporated. Compound 43 (38 mg, 0.083 mmol) was dissolved in dioxane/H.sub.2O 1:1 (3 mL) and the mixture was cooled to 0 C. before 1 M LiOH (140 L, 0.140 mmol) was added to the stirred solution. After 1 h the mixture was neutralized with 1 M hydrochloric acid and the solvent was evaporated and co-evaporated with toluene. The residue was coupled to deprotected 55 using the same HATU coupling conditions as in the synthesis of compound 48. Purification by HPLC (MeOH/H.sub.2O 90:10 with 0.2% triethylamine) gave 56 (56 mg, 88%) as a colorless sold. .sup.1H-NMR (300 MHz, CDCl.sub.3): 0.82-0.96 (m, 9H), 0.82-1.22 (m, overlapped, 6H), 1.23-1.40 (m, 2H), 1.44 (s, 9H), 1.50-1.69 (m, 4H), 1.71-1.87 (m, 2H), 1.95-2.06 (m, 1H), 2.07-2.22 (m, 1H), 2.28-2.54 (m, 3H), 2.60-2.75 (m, 1H), 3.08-3.28 (m, 1H), 3.30-3.49 (m, 1H), 3.70 (s, 3H), 3.94 (s, 3H), 4.28-4.38 (m, 1H), 4.41-4.57 (m, 2H), 5.17 (b, 1H), 6.54-6.70 (m, 2H), 6.74 (b, 1H), 6.95 (s, 1H), 7.09 (dd, J=2.5, 9.1 Hz, 1H), 7.39-7.55 (m, 5H), 7.98-8.10 (m, 3H); .sup.13C-NMR (75.5 MHz, CDCl.sub.3): 13.7, 18.1, 18.6, 19.2, 25.9, 28.0, 28.2, 29.6, 30.7, 34.6, 36.5, 37.6, 40.8, 47.4, 47.5, 52.1, 52.8, 55.5, 56.8, 58.9, 77.8, 82.0, 98.3, 107.5, 115.3, 118.1, 123.1, 127.5, 128.7, 129.1, 140.5, 151.4, 159.2, 160.7, 161.3, 171.0, 171.5, 172.3, 172.8, 173.0. MALDI-TOF-spectrum: (M+H).sup.+ calcd: 815.5, found: 815.7; (M+Na).sup.+ calcd: 837.4, found: 837.6; (M+K).sup.+ calcd: 853.4, found: 853.6.

Example 57

(155) ##STR00110##

(S)-2-{[(1R,2R,4S)-2-{(S)-1-[((S)-Cyclohexyl-methoxycarbonyl-methy)-carbamoyl]-2-methyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-pentanoic acid (57)

(156) Tert.butyl ester 56 (28 mg, 0.034 mmol) and triethylsilane (14 L, 0.088 mmol) was dissolved in DCM (2 mL) after which trifluoroacetic acid (2 mL) was added and the mixture was stirred for 2 h. Co-evaporation with toluene gave 57 (26 mg, 100%) as a colorless solid.

(157) .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.86-1.00 (m, 9H), 1.01-1.24 (m, 4H), 1.36-1.46 (m, 2H), 1.48-1.75 (m, 8H), 1.70-1.89 (m, overlapped, 1H), 1.96-2.12 (m, 1H), 2.22-2.40 (m, overlapped, 2H), 2.49-2.64 (m, 1H), 2.72-2.91 (m, 1H), 3.26-3.40 (m, overlapped, 1H), 3.50-3.68 (m, overlapped, 1H), 3.62 (s, 3H), 4.05 (s, 3H), 4.09-4.17 (m, 1H), 4.17-4.25 (m, 1H), 4.35-4.45 (m, 1H), 5.82 (b, 1H), 7.44 (dd, J=2.2, 9.3 Hz, 1H), 7.49 (s, 1H), 7.53 (d, J=2.2 Hz, 1H), 7.65-7.78 (m, 3H), 7.98-8.06 (m, 2H), 8.41 (dd, J=2.8, 9.3 Hz, 1H); .sup.13C-NMR (CD.sub.3OD, 75.5 MHz): 13.9, 18.8, 19.7, 20.2, 27.0, 29.7, 30.5, 31.8, 34.6, 37.7, 38.9, 41.1, 47.8, 52.3, 53.6, 56.9, 58.8, 58.9, 60.3, 83.8, 100.4, 102.2, 116.2, 121.6, 126.7, 129.8, 130.8, 133.3, 133.8, 143.5, 157.9, 166.5, 168.5, 173.3, 173.9, 175.5, 175.5, 175.6. MALDI-TOF-epectrum: (M+H).sup.+ calcd: 759.4, found: 759.7; (M+Na).sup.+ calcd: 781.4, found: 781.7; (M+K).sup.+ calcd: 797.4, found: 797.7.

Example 58

(158) ##STR00111##

(S)-2-{[(1R,2R,4S)-2-{(S)-1 [((S)Cyclohexyl-methoxycarbonyl-methyl)carbamoyl]-2-methyl-propylcarbamoyl}-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-butyric acid (58)

(159) The procedure described in example 42 was followed but with the use of L-2-amino-N-butyric acid tert.butyl ester instead of H-Nva-OtBu. The afforded compound was then reacted as described in example 43 which gave (1R,2R,4R)-2-((S)-1-tert-butoxycarbonyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy) cyclopentanecarboxylic acid methyl ester. Coupling of this compound with 55 as described in example 56 followed by esterhydrolysis as described in example 57 gave 58 as a colourless solid.

(160) .sup.1H-NMR (300 MHz, CD.sub.3OD): 0.82-0.99 (m, 9H), 0.82-1.40 (m, overlapped, 6H), 1.48-1.78 (m, 6H), 1.80-1.95 (m, 1H), 1.97-2.12 (m, 1H), 2.22-2.40 (m, overlapped, 2H), 2.51-2.64 (m, 1H), 2.71-2.90 (m, 1H), 3.16-3.39 (m, overlapped, 1H), 3.49-3.59 (m, 1H), 3.63 (s, 3H), 3.95 (s, 3H), 4.12-4.23 (m, 2H), 4.28-4.38 (m, 1H), 5.31 (b, 1H), 7.43 (dd, J=2.2, 9.3 Hz, 1H), 7.47 (s, 1H), 7.51 (s, 1H), 7.66-7.89 (m, 3H), 7.99-8.07 (m, 2H), 8.42 (d, J=9.1 Hz, 1H); .sup.13C-NMR (75.5 MHz, CD.sub.3OD): 10.7, 18.8, 19.7, 25.8, 27.0, 27.0, 29.7, 30.5, 31.8, 37.7, 38.9, 41.2, 47.9, 52.3, 55.3, 56.9, 58.8, 60.6, 83.6, 100.7, 102.2, 118.3, 121.5, 126.7, 129.8, 130.8, 133.7, 133.8, 143.9, 158.2, 166.4, 168.3, 173.3, 173.8, 175.2, 175.5, 175.6. MALDI-TOF-spectrum: (M+H).sup.+ calcd: 745.4, found: 744.9; (M+Na).sup.+ calcd: 767.4, found: 766.9; (M+K).sup.+ calcd: 783.5, found: 782.9.

Example 59

(161) ##STR00112##

(S)-2-{[(1R,2R,4S)-2-{((R)-1-[((R)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl}-4-(7ethoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-butyric acid (59)

(162) The procedure described in example 54 was followed but with the use of Boo-D-cyclohexyglycine Instead of Boc-L-cyclohexyglycine. The afforded compound was then reacted as described in example 55 followed by coupling with (1R,2R,4R)-2-((S)-1-tert-Butoxycarbonyl-pentylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarboxylic acid methyl ester as described in example 56. Removal of the ester group as described in example 57 gave compound 59 as a colourless solid. .sup.1H-NMR (CD.sub.3OD, 300 MHz): 0.82-1.02 (m, 9H), 1.04-1.42 (m, 6H), 1.52-1.80 (m, 6H), 1.80-1.95 (m, overlapped, 1H), 2.00-2.14 (m, 1H), 2.29-2.46 (m, 2H), 2.51-2.65 (m, 1H), 2.68-2.84 (m, 1H), 3.24-3.39 (m, overlapped, 1H), 3.47-3.60 (m, 1H), 3.67 (s, 3H), 4.07 (s, 3H), 4.18-427 (m, 2H), 4.28-4.38 (m, 11H), 5.64 (app. bs, 1H), 7.44 (d, J=2.3, 6.9 Hz, 1H), 7.42 (s, 2H), 7.67-7.81 (m, 3H), 8.04 (d, J=7.8 Hz, 2H), 8.41 (d, J=9.1 Hz, 1H); .sup.13C-NMR (CD.sub.3OD, 75.5 MHz): 10.8, 18.5, 19.6, 25.7, 27.1, 27.1, 30.1, 30.8, 31.9, 37.3, 38.2, 41.1, 47.8, 52.3, 55.4, 56.9, 59.0, 59.1, 60.2, 83.8, 100.5, 102.2, 116.3, 121.6, 126.8, 1298, 130.8, 133.6, 133.8, 143.7, 158.1, 166.5, 168.5, 173.4, 173.8, 175.4, 175.7, 175.7. MALDI-TOF-spectrum: (M+H).sup.+ calcd: 745.4, found: 745.4; (M+Na).sup.+ calcd: 767.4, found: 767.4; (M+K).sup.+ calcd: 783.5, found: 783.3.

Example 60

(163) ##STR00113##

Resin bound 2-tert.butoxycarbonylamino-3,3-dimethylbutyric acid (60)

(164) To Argonaut resin PS-TFP (1.38 mmol/g, 10 g) and 2-tert-butoxycarbonylamino-3,3-dimethyl-butyric acid (4.5 g, 20.7 mmol) was added dichloromethane (40 mL) and DMF (10 mL). To this mixture was added DMAP (1 g, 8.28 mmol) and then DIC (9.5 mL, 60.7 mmol). After 3 hrs of agitation at RT the resin was filtered and washed successively with DMF, THF, DCM, THF, DCM and ether and then dried in a vacuum.

Example 61

(165) ##STR00114##

[1-(2-Hydroxy-indan-1-ylcarbamoyl)-2,2-dimethyl-propyl]-carbamic acid tertbutyl ester (61)

(166) To a portion of 60 (200 mg) in DCM aminoindanol (0.14 mmol) was added. The mixture was agitated for 2 hrs. The liquid was filtered of and the resin washed with 2DCM. The combined liquids were combined and concentrated to dryness to afford the title compound (20.5 mg, 0.055 mmol) Purity>95% by HPLC. M+H.sup.+ 363.15. .sup.13C NMR .sub.c (100 MHz; CDCl.sub.3; Me.sub.4Si) 27.0, 28.5, 34.2, 39.8, 50.8, 57.9, 68.2, 73.7, 124.8, 125.6, 127.4, 128.5, 140.4, 171.6. .sup.1H NMR .sub.H (400 MHz; CDCl.sub.3; Me.sub.4Si) 1.07 (9H, s, CCH.sub.3), 1.44 (9H, s, OCCH.sub.3), 2.93 (1H, dd, J.sub.gem 16.4 Hz, J.sub.3,2 2.3 Hz, CH.sub.2), 3.15 (1H, dd, J.sub.gem 16.4 Hz, J.sub.3,25.2 Hz, CH.sub.2),

Example 62

(167) ##STR00115##

2-Amino-N-(2-hydroxy-indan-1-yl)-3,3-dimethyl butyramide (62)

(168) Compound 61 was kept in DCM-TFA 2:1 (2 mL) for 60 min at RT. The solution was co-evaporated with toluene to dryness.

Example 63

(169) ##STR00116##

(2-tert-Butoxycarbonylamino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (63)

(170) To a solution of 2-tert.butoxycarbonylamino-3,3-dimethyl butyric acid (500 mg, 2.16 mmol), Amino-cyclohexyl-acetic add methyl ester (444 mg, 2.59 mmol) and HATU (2 g, 5.40 mmol) in DMF (20 mL) was added diisopropylethylamine (1.88 mL, 10.8 mmol). The solution was stirred for 1 hrs at r.t. and diluted with dichloromethane (40 mL). This solution was washed with aqueous. NaHCO.sub.3 (sat) and water (2), dried and concentrated. The product was >95% pure. M+H.sup.+385.4.

Example 64

(171) ##STR00117##

{1-[(Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propyl}-carbamic acid tert-butyl ester (64)

(172) To compound 63 in EtOH-THF 1:2 was added a large excess of methylamine (30% in water) and left at rt. for 2 weeks. The solution was concentrated to dryness and the residue subjected to a short silica gel column eluted with 2% MeOH in dichloromethane to give a pure (>95%) product M+H.sup.+ 384.5.

Example 65

(173) ##STR00118##

2-Amino-N-(cyclohexyl-methylcarbamoyl-methyl)-3,3-dimethyl-butyramide (65)

(174) Compound 64 was kept in dichloromethane-trifuoroacetic acid 2:1 for 1 h at rt and concentrated to dryness. The residue was dried in a vacuum for 16 hr. Reversed phase C18 HPLC showed >95% purity M+H.sup.+ 283.1.

Example 66

(175) ##STR00119##

1-(2-Amino-4-methoxyphenyl)ethanone (66)

(176) m-Anisidine (10.0 g, 82 mmol) was dissolved in CH.sub.2Cl.sub.2 (50 mL), and the solution was cooled to 50 C. BCl.sub.3(1 M in CH.sub.2Cl.sub.2, 82 mL, 82 mmol) was added slowly during 20 min, after which the mixture was stirred at 50 C. for 30 min, followed by sequential addition of AcCl (6.0 mL, 84 mmol) and AlCl.sub.3 (11 g, 82 mmol). The mixture was stirred at 50 C. for 1 h and was then allowed to assume rt. Alter stirring at rt overnight, the solution was heated at 40 C. for 4 h, after which the mixture was poured over ice. The aqueous mixture was made alkaline with 10% NaOH (w/v) and extracted with EtOAc (4200 mL). The combined organic phases were washed with brine, dried (MgSO.sub.4), and evaporated to give a black solid, which was purified by flash column chromatography (ether/CH.sub.2Cl.sub.2 20:80). The resulting solid was recrystallized from ether/hexane to give compound 93 as shiny tan leaflets (5.6 g, 42%).

Example 67

N-(tert-Butyl)-N-isopropylthiourea (67)

(177) To a solution of tert-butylisothiocyanate (5.0 mL, 39 mmol) in CH.sub.2Chi (200 mL) were added isopropylamine (4.0 mL, 47 mmol) and disopropylethylamine (DIEA) (6.8 mL, 39 mmol), and the mixture was stirred at rt for 2 h. The reaction mixture was diluted with EtOAc, washed with 10% citric acid (2), saturated NaHCO.sub.3 (2), H.sub.2O (2), and brine (1). The organic layer was dried (MgSO.sub.4) and evaporated to yield the tide compound (3.3 g, 52%) as a white solid which was used without further purification.

Example 68

N-Isopropylthiourea (68)

(178) Compound 67 (3.3 g, 20 mmol) was dissolved in conc. HCl (45 mL) and the solution was refluxed for 40 min. The mixture was allowed to cool to rt and then cooled in an ice bath and basified to pH 9.5 with sold and saturated NaHCO.sub.3, after which the product was extracted into EtOAc (3). The combined organic phases were washed with H.sub.2O (2) and brine (1), dried (MgSO.sub.4), and evaporated to yield the crude title compound (2.1 g, 90%) which was used without further purification.

Example 69

(179) ##STR00120##

2-(Isopropylamino)-1,3-thiazole-4-carboxylic acid hydrobromide (69)

(180) A suspension of compound 68 (2.1 g, 18 mmol) and 3-bromopyruvic acid (3.0 g, 18 mmol) in dioxane (180 mL) was heated to 80 C. Upon reaching 80 C. the mixture became clear, and soon thereafter the product started to precipitate as a white solid. After 2 h of heating, the reaction mixture was cooled to rt and the precipitate was filtered off and collected. This yielded pure title product (4.4 g, 94%).

Example 70

(181) ##STR00121##

N-(2-Acetyl-5-methoxyphenyl)-2-(isopropylamino)-1,3-thiazole-4-carboxamide (70)

(182) A mixture of compound 69 (4.4 g, 16.5 mmol) and the aniline derivative 66 (2.75 g, 16.5 mmol) in pyridine (140 mL) was cooled to 30 C. (upon cooling, the clear solution became partially a suspension). POCl.sub.3 (3.3 mL, 35 mmol) was added slowly over a 5 min period. The mixture was stirred at 30 C. for 1 h, and was then allowed to assume rt. After stirring at rt for 1.5 h the reaction mixture was poured over ice, and the pH was adjusted to about 9-10 using solid and saturated NaHCO.sub.3. The crude product was extracted into CH.sub.2Cl.sub.2 (3) and the combined organic phases were dried (MgSO.sub.4) and evaporated. The crude dark-beige solid was purified by flash column chromatography (hexane/EtOAc 55:45) to give compound 70 (5.6 g, 76%) as a pale yellow solid.

Example 71

(183) ##STR00122##

2-[2-(Isopropylamino)-1,3-thiazol-4-yl]-7-methoxyquinolin-4-ol (71)

(184) A solution of tBuOK (2.42 g, 21 mmol) in anhydrous t.BuOH (40 mL) was heated to reflux Compound 70 (1.8 g, 5.4 mmol) was added portion-wise over a 5 min period, and the dark red solution formed was stirred at reflux for an additional 20 min. The mixture was cooled to rt, and HCl (4 M in dioxane, 8.0 mL, 32 mmol) was added, after which the reaction mixture was concentrated under vacuum. In order to assure that all of the HCl and dioxane were removed, the crude product was re-dissolved in CH.sub.2Cl.sub.2 twice and thoroughly evaporated to obtain the slightly impure HCl salt of compound 71 (1.62 g) as a brown solid. The product was dissolved in CH.sub.2C.sub.1 and washed with saturated NaHCO.sub.3, after which the aqueous phase was extracted several times with CH.sub.2Cl.sub.2. The combined organic phases were dried (MgSO.sub.4) and evaporated to give compound 71 (1.38 g, 81%) as a light brown solid (>95% pure according to HPLC tests). .sup.1H-NMR (MeOH-d.sub.4, 400 MHz): 1.30 (d, J=8.0 Hz, 6H), 3.93 (s, 3H), 3.95-4.07 (m, 1H), 6.73 (s, 1H), 8.99 (dd, J=2.4, 9.2 Hz, 1H), 7.26 (d, J=2.4 Hz, 1H), 7.37 (s, 1H), 8.10 (d, J=9.2 Hz, 1H).

Example 72

(185) ##STR00123##

(1R,4R,5R)N-[(1S)-1-[[[(1S)-1-Cyclohexyl-2-(methylamino)-2-oxoethyl]amino]carbonyl]-2,2-dimethylpropyl]-3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxamide (72)

(186) To a solution of compound 32 (53 mg, 0.34 mmol) in DMF (9 mL) was added compound 65 (80 mg, 0.28 mmol) and DIEA (290 L, 1.66 mmol). The solution was cooled to 0 C. and HATU (127 mg, 0.33 mmol) was added. After stirring at 0 C. for 1 h and at it for 1 h the solvent was evaporated, and the crude product was purified by flash column chromatography (EtOAc/toluene 2:1) to give compound 72 (110 mg, 92%) as a white solid.

Example 73

(187) ##STR00124##

(1R)-1-[[[1R,2R,4R)-2-[[[(1 S)-1-[[[(1 S)-1-Cyclohexyl-2-(methylamino)-2-oxoethyl]amino]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]-4-hydroxycyclopentyl]carbonyl]amino]-2-ethenyl-cyclopropanecarboxylic acid ethyl ester (73)

(188) Compound 72 (60 mg, 0.14 mmol) was dissolved in dioxane (3.5 mL) and H.sub.2O (2.5 mL) and the solution was cooled to 0 C. LiOH (1 M, 280 L, 0.28 mmol) was added dropwise during 5 min, after which the reaction mixture was stirred at 0 C. for 40 min. The pH was adjusted to 7 using 1 M HCl, and the solvents were evaporated. The residue was suspended in DMF (5 mL) and 1-amino-2-vinyl-cyclopropanecarboxylic acid ethyl ester (32 mg, 0.17 mmol), and DIEA (146 L, 0.84 mmol) were added. After cooling to 0 C. HATU (64 mg, 0.17 mmol) was added and the mixture was stirred at 0 C. for 1 h and at t for 1 h. The solvent was evaporated and the product was purified using flash column chromatography (EtOAc/MeOH 9:1) to give compound 73 (87 mg, 82%) as a white solid.

Example 74

(189) ##STR00125##

tert-Butyl (1R,2R,4R)-2-[[[(1R)-1-(ethoxycarbonyl)-2-vinylcyclopropyl]amino]carbonyl]-4-[[2-[2-(Isopropylamino)-1,3-thiazol-4-yl]-7-methoxyquinolin-4-yl]oxy]cyclopentanecarboxylate (74)

(190) The title compound was prepared according to the procedure described in example 76 method A but with the use of compound 34 instead of compound 73. (Note: 4 equivalents of Ph.sub.3P and DIAD were used. Chromatography eluent Toluene/EtOAc 1:1.)

Example 75

(191) ##STR00126##

(1R,2R,4R)-2-[[[(1R)-1-(Ethoxycarbonyl)-2-vinylcyclopropyl]amino]carbonyl]4-[[2-[2-(isopropylamino)-1,3-thiazol-4-yl]-7-methoxyquinolin-4-yl]oxy]cyclopentanecarboxylic acid (75)

(192) To a solution of compound 74 (20 mg, 30 umol) in CH.sub.2Cl.sub.2 (2 mL) was added TFA (2 mL) and Et.sub.3SiH (10 uL, 63 umol). After 2 h the volatiles were evaporated and the product was used without any purification step. Compound 75:18 mg, quant as a white solid.

Example 76

(193) ##STR00127##

(1R)-1-[[[(1R,2R,4S)-2-[[[(1S)-1-[[[(1 S)-1-Cyclohexyl-2-(methylamino)-2-oxoethyl]amino]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]-4-[[7-methoxy-2-[2-[(1-methylethyl)amino]-thiazolyl]-4-quinolinyl]oxy]cyclopentyl]carbonyl]amino]-2-ethenyl-cyclopropanecarboxylic acid ethyl ester (76)

(194) Method A:

(195) To a solution of compound 73 (59 mg, 0.10 mmol) in dry THF (4 mL) was added the quinoline 71 (49 mg, 0.16 mmol) and Ph.sub.3P (65 mg, 0.25 mmol). After cooling to 0 C. DIAD (50 uL, 0.25 mmol) was added dropwise during 5 min. The solution was stirred at 0 C. for 1 h and at it for 48 h. The solvent was evaporated and the remainder was purified using flash column chromatography (CHCl.sub.3/2 M NH.sub.3 in MeOH 95:5) to give compound 76 (9 mg, 10%) as a white solid.

(196) Method B:

(197) Compound 75 was coupled to compound 65 according to the procedure in example 72 which gave the title compound (82%).

Example 77

(198) ##STR00128##

(1R)-1-[[[(1R,2R,4S)-2-[[[(1S)-1-[[[(1 S)-1-Cyclohexyl-2-(methylamino)-2-oxoethyl]amino]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]-4-[[7methoxy-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]cyclopentyl]carbonyl]amino]-2-ethenyl-cyclopropanecarboxylic acid (77)

(199) Compound 76 (8 mg, 9 mol) was dissolved in a mixture of MeOH (150 L) and THF (100 uL). A solution of LiOH (1 mg, 42 mol) in H.sub.2O (25 L) was added and the mixture was stirred at 50 C. overnight. The solution was neutralized with HOAc and evaporated. The residue was suspended in CH.sub.2C and washed with H.sub.2O. The organic phase was evaporated to give the title compound (8 mg, quant.) as a white solid.

(200) .sup.1H-NMR (MeOH-d.sub.4, 400 MHz) (mixture of rotamers): 0.60-1.33 (m, 21H), 1.35-1.73 (m, 12H), 1.90-2.42 (m, 2H), 2.51-2.75 (m, 6H), 3.20-3.38 (m, 1H), 3.85 (s, 3H), 3.95-4.28 (m, 1H), 4.91-5.02 (m, 1H), 5.12-5.23 (m, 1H), 5.64-5.83 (m, 1H), 7.01-7.11 (m, 1H), 7.25-7.40 (m, 1H), 7.42-7.57 (m, 1H), 7.85-8.08 (m, 1H).

Example 78

(201) ##STR00129##

2-Amino-3,3-dimethyl-N-thiophen-2-yl-methyl-butyramide (78)

(202) The title compound was prepared as described in example 61 but with the use of thiophene-2-methylamine instead of aminoindanole followed by removal of the Boc group as described in example 62.

Example 79

(203) ##STR00130##

2-Amino-N-(6-hydroxy-4,5,6,7-tetrahydro-benzo[b]thiophen-5-yl)-3,3-dimethyl-butyramide (79)

(204) The title compound was prepared as described in example 61 but with the use of 2-amino-4,5,6,7-tetrahydro-benzo[b]thiophen-5-ol instead of aminoindanole followed by removal of the Boc group as described in example 62.

Example 80

(205) ##STR00131##

2-Amino-N-(2-diethylamino-ethyl-3,3-dimethyl-butyramide (80)

(206) The title compound was prepared as described in example 61 but with the use of N,N-diethylethylenediamine instead of aminoindanole followed by removal of the Boc group as described in example 62.

Example 81

(207) ##STR00132##

2-Amino-N-[2-(2-methoxy-phenoxy)-ethyl]-3,3-dimethyl-butyramide (81)

(208) The title compound was prepared as described in example 61 but with the use of 2-methoxyphenoxyethylamine instead of aminoindanole followed by removal of the Boc group as described in example 62.

Example 82

(209) ##STR00133##

2-Amino-1-(3-hydroxy-pyrrolidin-1-yl)-3,3-dimethyl-butan-1-one (82)

(210) The title compound was prepared as described in example 61 but with the use of (R)-3-pyrrolidinone instead of aminoindanole followed by removal of the Boc group as described in example 62.

Example 83

(211) ##STR00134##

2-Amino-N-(1,1-dioxo-tetrahydro-1-thiophen-3-yl)-3,3-dimethyl-butyramide (83)

(212) The title compound was prepared as described in example 61 but with the use of 2-methoxyphenoxyethylamine instead of aminoindanole followed by removal of the Boc group as described in example 62.

Example 84

(213) ##STR00135##

Carbamic acid, [(1 S)-1-[[(phenylsulfonyl)amino]carbonyl]butyl]-, phenylmethyl ester (84)

(214) To a stirred solution of Z-Nva-OH (150 mg, 0.59 mmol) in THF (6 mL), CDI (400 mg, 2.4 mmol) was added. The slurry was agitated for 30 min at RT followed by the addition of DBU (200 uL, 1.3 mmol) and a solution of benzenesulfonamide (250 mg, 1.59 mmol) in THF (2 mL). The mixture was stirred at 60 C. for 48 hrs followed by concentration to dryness. The residue was dissolved in MeOH and subjected to HPLC purification to give the title compound (118.5 mg, 0.304 mmol). Purity>95% by HPLC. MH.sup.+ 389.0, +Na 412.96.

Example 85

(215) ##STR00136##

(2S)-2-Amino-N-(phenylsulphonyl)pentanamide (85)

(216) Compound 84 was dissolved in MeOH (5 mL) followed by the addition of Pd/C and subjected to hydrogenation for 2 hrs. The slurry was filtered through celite, washed with MeOH and concentrated to dryness to give the title compound. Yield 100%. M+H.sup.+ 257.3.

Example 86

(217) ##STR00137##

4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentane-12-dicarboxylic acid 1-{[1-(cyclohexylmethyl-carbamoyl)-2-methyl-propyl]-amide} 2-[(1-phenylmethanesulfonylaminocarbonyl-2-vinyl-cyclopropyl)-amide] (86)

(218) N-(tert-Butoxycarbonyl)-L-valine was attached to Argonaut resin PS-TFP as described in example 60 followed by reaction with cyclohexanemethylamine as described in example 61 and removal of the Boc group as described in example 62. The afforded amine was used in a coupling reaction with compound 35 as described in example 39 followed by hydrolysis of the ethyl ester as described in example 40 which gave 1-{[2-[1-(cyclohexylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic add. The afforded add was then treated as described in example 94 but using toluenesulphonamide instead of cyclopropylsulphonamide which gave the title compound. Yield 6%. Purity>95% by HPLC. M+H.sup.+ 864.32.

Example 87

(219) ##STR00138##

(220) Acetic acid (1S,2R)-1-((2S)-2-amino-3,3-dimethyl-butyrylamino)-indan-2-yl ester (87) A solution of compound 61 (4 g) was kept in pyridine-acetic anhydride 2:1 for 30 min. DCM was added and the solution was washed with citric acid (aq) and NaHCO.sub.3 (aq). The organic layer was concentrated to dryness which gave the acetylated product>90% pure by HPLC. The afforded compound was then kept in a solution of 30% TFA In DCM for 1.5 hrs and then concentrated to dryness. Co-evaporation twice from toluene gave the title product>90% pure by HPLC.

Example 88

(221) ##STR00139##

(2S)-Methanesulphonic acid 2-tert.butoxycarbonylamino-4-methyl-pentyl ester (88)

(222) To a solution of ((S)-1-hydroxymethyl-3-methylbutyl)-carbamic acid tert-butyl ester (25 g, 115 mmol) in dichloromethane (500 mL) cooled by an ice-water bath was successively added disopropylethylamine (35.7 g, 276 mmol) and methanesulphonyl chloride (15.81 g, 138 mmol). The resulting solution was stirred over night during which time the mixture was allowed to gradually warm up to ambient temperature. The mixture was washed successively with water, 10% citric acid (aq), water and saturated NaHCO.sub.3 (aq), then dried with Na.sub.2SO.sub.4 and concentrated to a brown solid (32.6 g, 96%) which was used in the next reaction without further purification.

Example 89

(223) ##STR00140##

ii) ((1 S)-1-Azidomethyl-3-methyl-butyl)carbamic acid tert.butyl ester (89)

(224) The mesylate from example 88 (32.6 g, 110 mmol) was treated with sodium azide (21.45 g, 330 mmol) in DMF at 80 C. for 24 hrs. The solvent was evaporated, the residue was taken up in DCM, filtered and washed with saturated NaHCO.sub.3 (aq). The solution was dried with Na.sub.2SO.sub.4 and concentrated to a brown oil which was purified by flash chromatography using a gradient of ethyl acetate and hexane to afford the title compound as a white solid (19.55 g, 73%).

Example 90

(225) ##STR00141##

(1S)-1-Azidomethyl-3methyl-butylamine (90)

(226) ((1 S)-1-Azidomethyl-3-methyl-butyl)-carbamic acid tert-butyl ester (9.64 g, 39.78 mmol) was treated with TFA (30 mL) in DCM (150 mL) for 3 hrs, the mixture was evaporated under reduced pressure and the residue was dissolved in ethyl acetate and washed with aqueous 1 M K.sub.2CO.sub.3, dried with Na.sub.2SO.sub.4 and concentrated to a yellow liquid (4.55 g, 80%).

Example 91

(227) ##STR00142##

1-{[2-Hex-5-enylcarbamoyl-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino}-2-vinyl-cycloprpanecarboxylic acid ethyl ester (91)

(228) The tert.butyl ester of compound 35 was removed by treatment with triethylsilane as described in Example 39. The afforded add (724 mg, 1.33 mmol), hex-5-enylamine hydrochloride (271 mg, 2 mmol) and diisopropylethylamine (1.85 ml, 10.65 mmol) was dissolved in DMF (20 ml) and cooled to 0 C. After 30 min. HATU (608 mg, 1.6 mmol) was added and the flask was removed from the ice-bath. The reaction was followed with LC-MS. After 3 h the reaction mixture was extracted between EtOAc (100 ml) and aqueous sodium hydrogencarbonate (15 ml). The EtOAc-phase was dried over magnesium sulphate, evaporated and purified by chromatography on silica gel (25% EtOAc in hexane.fwdarw.50% EtOAc in hexane) to give the pure title product (726 mg, 87%). MS (M+H.sup.+): 525.8

Example 92

(229) ##STR00143##

17-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester (92)

(230) Compound 91 (363 mg, 0.58 mmol) was dissolved in degassed dichloromethane (100 ml). Hoveyda-Grubbs catalyst 2nd generation (26 mg, 0.041 mmol) was added and the mixture was refluxed under argon atmosphere overnight. The reaction mixture was evaporated on silica and purified by silica gel chromatography (50% EtOAc in hexane.fwdarw.70% EtOAc in hexane) to give the pure title product (111 mg, 32%). MS (M+H.sup.+): 597.7

Example 93

(231) ##STR00144##

17-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic add (93)

(232) Compound 92 (96 mg, 0.159 mmol) was dissolved in tetrahydrofuran (10 ml), methanol (5 ml) and water (4 ml) Lithium hydroxide (40 mg, 1.67 mmol) was dissolved in water (1 ml) and added. The reaction mixture was heated to 65 C. After 3 h the reaction mixture was cooled, acidified with aqueous HCl (pH5), evaporated on silica and purified by silica gel chromatography (10% MeOH in dichloromethane.fwdarw.15% MeOH in dichloromethane) to give the pure title product (65 mg, 72%). MS (M+H.sup.+): 569.8

Example 94

(233) ##STR00145##

Cyclopropanesulphonic add [17-(7-methoxy-2-phenyl-quinolin-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*octadec-7-ene-4-carbonyl]-amide (94)

(234) Compound 93 (65 mg, 0.12 mmol), DMAP (21 mg, 0.17 mmol) and EDAC (44 mg, 0.23 mmol) was dissolved in DMF (0.2 ml). The reaction mixture was stirred for 6 h at R.T. whereafter cyclopropylsulfonamide (69 mg, 0.57 mmol) and DBU (80 l, 0.57 mmol) was added. After stirring at R.T overnight the reaction mixture was extracted between EtOAc (80 ml) and aqueous citric add (10%, 215 ml). The organic phase was dried over MgSO.sub.4, evaporated on silica and purified twice by chromatography on silica gel (5% MeOH in dichloromethane.fwdarw.15% MeOH in dichloromethane) which gave a syrup. This syrup was dissolved in a small volume acetonitrile and precipitated with ethyl ether to give the pure title product (19 mg, 23%). MS (M+H.sup.+): 673.2

Example 95

(235) ##STR00146##

1-{[2-Hex-5-enyl-methyl-carbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino-2-vinyl-cyclopropanecarboxylic add ethyl ester (95)

(236) The tert.butyl ester of compound 35 was removed according to the procedure described in Example 39. The afforded acid (850 mg, 1.56 mmol), N-methyl hex-6-enylamine hydrochloride (380 mg, 2.5 mmol) and diisopropylethylamine (2.3 ml, 13.4 mmol) was dissolved in DMF (60 mL) and cooled to 0 C. After 30 min. HATU (0.76 mg, 2.0 mmol) was added and the flask was removed from the ice-bath. The reaction was followed with TLC. After 2 h the reaction mixture was added to 5% citric acid and extracted three times with ethyl acetate. The organic phase was dried over sodium sulphate and evaporated under reduced pressure. The crude product was purified by silica gel chromatography which gave the title product (820 mg, 82%.

Example 96

(237) ##STR00147##

17-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-3-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester (96)

(238) Compound 95 (648 mg, 1.01 mmol) was dissolved in degassed dichloroethane (500 mL). Hoveyda-Grubbs catalyst 2:nd generation (35 mg, 0.055 mmol) was added and the mixture was refluxed under argon atmosphere overnight. The reaction mixture was evaporated on silica and purified by chromatography on silica gel (30% EtOAc in toluene.fwdarw.50% EtOAc in toluene) to give the pure title product (230 mg mg, 37%). MS (M+H.sup.+): 612.8

Example 97

(239) ##STR00148##

17-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic add ethyl ester (97)

(240) Compound 96 (260 mg, 0.42 mmol) was dissolved in 1,4-dioxan (20 mL), 1.0 M Lithium hydroxide (6.0 ml) was added and the mixture was stirred at room temperature overnight and then for six hours at 60 C. The mixture was added to 5% citric acid and extracted 3 times with ethyl acetate. The organic phase was dried over sodium sulphate and evaporated under reduced pressure. The crude product was purified by silica gel chromatography with DCM and 5% MeOH which gave the title product (130 mg, 53%). MS (M+H): 584.7

Example 98

(241) ##STR00149##

Cyclopropanesulphonic acid [17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*octadec-7ene-4-carbonyl]-amide (98)

(242) Compound 97 (58.3 mg, 0.1 mmol), DMAP (18.3 mg, 0.15 mmol) and EDAC (38.7 mg, 0.2 mmol) was dissolved in DMF (1.0 mL). The reaction mixture was stirred overnight at R.T. whereafter cyclopropylsulphonamide (60.5 mg, 0.5 mmol) and DBU (76 g, 0.5 mmol) was added. After stirring at R.T overnight the reaction mixture was added to 5% citric acid and extracted three times with ethyl acetate. The organic phase was dried over sodium sulphate and evaporated. The afforded residue was purified two times by silica gel chromatography which gave the title product (20 mg). MS (M+H) 687.8.

Example 99

(243) ##STR00150##

[4-Cyclopropanesulphonylaminocarbonyl-17(7-methoxy-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6]octadec-7-en-13-yl]-carbamic acid tert.butyl ester (99)

(244) N-Hex-5-en-(E)-ylidene-hydrazinecarboxylic acid tert.butyl ester was prepared according to the procedure described in Example 48 and 47 but starting from hex-5-en-ol instead of hept-6-en-ol. Compound 35 was treated as described in Example 48 but using the above described N-Hex-5-en-(E)-ylidene-hydrazinecarboxylic acid tert.butyl ester instead of the corresponding hept-6-en derivative followed by macrocyclisation as described in Example 49 and hydrolysis of the ethyl ester as described in Example 50 gave the acid. The afforded acid (58 mg, 0.0848 mmol) was dissolved in dry DMF (7 mL) and DIEA was added drop wise during one minute. The solution was stirred at room temperature for 1 h prior to the addition of a solution containing cyclopropylsulfonamide (41 mg, 0.338 mmol), DMAP (41.3 mg, 0.338 mmol) and DBU (50 L, 0.338 mmol) in dry DMF (1.5 mL). The solution was stirred at room temperature for 5 days. The solution was diluted with EtOAc (50 mL) and washed with sat NaHCO.sub.3. The aqueous phase was extracted with DCM. The combined organic layers were dried, concentrated and subjected to purification by HPLC, which gave the title compound as a white solid (14.3 mg, 0.018 mmol), Purity by HPLC>95%, M+H.sup.+ 788.3.

Example 100

(245) ##STR00151##

Cyclopropanesulphonic acid[13-amino-17-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carbonyl]-amide trifluoroacetic add salt (100)

(246) Compound 99 (2.4 mg, 0.00304 mmol) was kept in TFA-DCM 1:2 (3 mL) at room temperature for 60 min. Toluene (3 mL) was added. The sample was co-evaporated to dryness to afford the title compound (2.1 mg, 0.0028 mmol) Purity by HPLC>95%. M+H.sup.+ 688.3.

Example 101

(247) ##STR00152##

3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid hex-5-enyl-methylamide (101)

(248) To HATU (2.17 g, 5.7 mmol) and N-methyl hex-5-enylamine hydrochloride (8.47 mmol) in 5 mL DMF, under argon in an ice bath, were added 1R,4,5R-3-oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid (835.6 mg, 5.35 mmol) in 11 mL DMF followed by DIEA (2.80 mL, 16 mmol). After stirring for 40 min, the mixture was stirred at rt for 5 h. The solvent was evaporated, the residue dissolved in EtOAc (70 mL) and washed with saturated NaHCO.sub.3 (10 mL). The aqueous phase was extracted with EtOAc (225 mL). The organic phases were combined, washed with saturated NaCl (20 mL), dried over Na.sub.2SO.sub.4, and evaporated. Flash column chromatography (150 g silica gel, 2/1 EtOAcpetroleum ether (PE), TLC detection by aqueous KMnO4, Rf 0.55 in 4/1 EtOAcPE) gave the compound as a yellow oil (1.01 g, 75%).

Example 102

(249) ##STR00153##

4-Hydroxycyclopentane-1,2-dicarboxylic acid 1-[(1-cyclopropanesulphonylaminocarbonyl-2-vinylcyclopropyl)-amide] 2-(hex-5-enyl-methylamide (102)

(250) LiOH solution (0.15M, 53 mL, 8 mmol) was added to the lactone amide 101 (996 mg, 3.96 mmol) in an ice bath and stirred for 1 h. The mixture was acidified to pH 2-3 with 1N HC and evaporated, co-evaporated with toluene several times, and dried under vacuum overnight (1R,2S)-cyclopropanesulfonic acid (1-amino-2-vinyl-cyclopropanecarbonyl)amide hydrochloride (421 mmol) and HATU (1.78 g, 4.68 mmol) were added. The mixture was cooled in an ice bath under argon, DMF (25 mL) and then DIEA (2.0 mL, 11.5 mmol) were added. After stirring for 30 min, the mixture was stirred at rt for 3 h. After evaporation of solvent, the residue was dissolved in EtOAc (120 mL), washed successively with 0.5 N HCl (20 mL) and saturated NaCl (220 mL), and dried over Na.sub.2SO.sub.4. Flash column chromatography (200 g YMC silica gel, 2-4% MeOH in CH.sub.2Cl.sub.2 gave white solids (1.25 g, 66%).

Example 103

(251) ##STR00154##

Cyclopropanesulphonic acid (17-hydroxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carbonyl)-amide (103)

(252) The cyclopentanol 102 (52.0 mg, 0.108 mmol) was dissolved in 19 mL 1,2-dichloroethane (bubbled with argon prior to use). The Hoveyda-Grubbs 2.sup.nd generation catalyst (6.62 mg, 10 mole %) was dissolved in DCE (20.5 mL) and added. The green solution was bubbled with Ar for 1 min. Aliquots (4 mL each) were transferred Into five 2 to 5-mL microwave tubes. To the last tube was added 0.8 mL rinsing with solvent. Each tube was heated by microwave (rt to 160 C. In 5 min). All aliquots were combined and the solvent evaporated. Flash column chromatography (silica gel, 3-7% MeOH in CH.sub.2Cl.sub.2) gave 24.39 mg solids (Rf 0.28 in 10% MeOHCH.sub.2C.sub.1 with two spots). The solids were combined with a 9.86-mg sample and subjected to a second chromatography (2-8% MeOH in EtOAc) to give cream solids (23 mg) with 80% of the desired compound (26% yield).

Example 104

(253) ##STR00155##

Cyclopropanesulphonic add {17-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carbonyl)-amide (104)

(254) DIAD (22 uL, 0.11 mmol) was added to a mixture of the metathesis product 103 (23 mg), 2-(4-isopropyl-1,3-thiazol-2-yl)-7-methoxyquinolin-4-ol (24 mg, 0.08 mmol), and PPh.sub.3(30 mg, 0.11 mmol) in 1 mL dry THF, in an ice bath. The mixture was stirred at rt overnight and then evaporated. The residue (1.2 mL of a 1.5-mL MeCN solution) was purified by prep-HPLC (Hypercarb 7 uL 100212 mm, 40% to 99% aqueous MeCN in 10 min) to give 3.18 mg MV062308 as cream solids (13% yield). 1H NMR (DMSO-d6) ppm: major rotamer 0.99 (m, 2H), 1.11 (m, 2H), 1.20-1.30 (m, 2H), 1.37 and 1.38 (2d, J=7.0 Hz, 6H), 1.46-1.58 (m, 2H), 1.70 (m, 1H), 1.85 (m, 1H), 1.90 (dd, J=8.5, 6.0 Hz, 1H), 2.08 (br, 1H), 2.26 (m, 1H), 2.38 (m, 1H), 2.52-2.82 (m, 3H), 2.90-2.97 (m, 2H), 3.06 (s, 3H), 3.21 (m, 1H), 3.40-3.56 (m, 2H) 3.97 (s, 3H), 4.60 (m, 1H), 5.04 (m, 1H), 5.41 (br, 1H), 5.66 (m, 1H), 7.16 (m), 7.58 (br), 8.02 (m), 10.92 (s, 1H)

Example 105

(255) ##STR00156##

N-{4-[4-Cyclopropanesulphonylaminocarbonyl-13-methyl-2, 14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6]octadec-7-en-17-yloxy)-7methoxy-quinolin-2-yl]-thiazol-2-yl}-3,3dimethylbutyramide (106)

(256) Treatment of compound 103 with 4-hydroxy-7-methoxy-2-[2-(2,2-dimethylbutanoyl)aminothiazol-4-yl]quinoline as described hi Example 104 gave the title compound.

(257) LCMS: retention time 2.30 in gradient 30%-80% B in 3 min(flow. 0.8 mL/min, UV 220 nm, ACE C8 35 mm; mobile phase A 10 mM NH.sub.4Ac in 90% H.sub.2O, B 10 mM NH.sub.4Ac in 90% ACN), (M+1).sup.+=807.

Example 106

(258) ##STR00157##

1-{[2-(Hex-5-enyl-methyl-carbamoyl)-4-hydroxy-cyclopentanecarbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid ethyl ester (106)

(259) Reaction of compound 101 as described hi example 102 but using 1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester instead of (1R,2S)-cyclopropanesulfonic acid (1-amino-2-vinyl-cyclopropanecarbonyl)amide hydrochloride gave the title compound.

Example 107

(260) ##STR00158##

1-{(4-(4-Bromo-benzensulphonyloxy-2-(hex-5-enyl-methyl-carbamoyl)-cyclopentanecarbonyl-amino}2-vinyl-cyclopropanecarboxylic add ethyl ester (107)

(261) Compound 106 (115 mg, 0.286 mmol) was dissolved in toluene 5 ml and dichloromethane 1 ml. DABCO (2.2.2-diazobicyclooctane) (96 mg, 0.857 mmol, 3 eq.) was added to the solution, followed by addition of BsCl (109 mg, 0.428 mmol, 1.5 eq). The reaction was stirred at room temperature overnight, diluted with toluene (+10% ethyl acetate), washed with saturated sodium bicarbonate, brine, dried over sodium sulphate and evaporated. The desired product was obtained by column chromatography (eluent EtOAc) R.sub.f 0.25). Conversion 80%. Yield 106 mg.

Example 108

(262) ##STR00159##

17-(4-Bromo-benzensulphonyloxy)-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester (108)

(263) Compound 107 (106 mg, 0.169 mmol) was dissolved in dichloromethane (40 ml) and degassed by bubbling nitrogen through the solution for 20 min. Hoveyda-Grubbs catalyst 1st generation (10 mg, 0.017 mmol, 10 mol %) was then added and the mixture was refluxed under nitrogen atmosphere overnight. The reaction mixture was then cooled down to room temperature and MP-TMT palladium scavenger (approx 100 mg) was added and stirred for 2.5 h. The scavenger was removed by filtration and washed with 50 ml of dichloromethane. The solution obtained was concentrated by rotary evaporation. The crude was purified by column chromatography (EtOAc) to give 61 mg of product. Yield 60%.

Example 109

(264) ##STR00160##

17-[2-(2-isopropylamino-triazol-4-yl)-7-methoxy-quinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester (109)

(265) 2-(Isopropylamino-thiazol-4-yl)-7-methoxy-quinolin-4-ol (220 mg, 0.7 mmol) (prepared as described in WO 00/59929) was dissolved in 7 mil of NMP (N-methyl pyrrolidinone), one spoon of Cs.sub.2CO.sub.3 was added, stirred at 60 C. for 1.5 h. Then compound 108 (150 mg, 0.24 mmol) was added. The reaction mixture was stirred at 80 C. overnight. Was diluted with chloroform and washed with sodium bicarbonate, brine. Water phases were back-extracted with chloroform. The combined organic layers were dried over sodium sulphate and evaporated. The crude product was purified by preparative HPLC (Gilson) (MeOHH.sub.2O, 65%) to give 21 mg of product (yield 13%) as well as 12 mg of isomer.

Example 110

(266) ##STR00161##

17-[2-(2-Isopropylamino-thiazol-4-yl)-7-methoxy-quinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid (110)

(267) To the solution of the ester 109 (21 mg, 0.031 mmol) in a mixture of THF (02 ml) and methanol (0.3 ml) was added solution of LiOH (4 mg, 0.17 mmol) in 0.15 ml water. The resulting mixture was stirred at 60 C. for 3.5 h. After cooling to room temperature, acetic acid was added (30 eq). The mixture was co-evaporated with toluene. The residue was distributed between chloroform and water, the water phase was extracted with chloroform 3 times, the organic phases were combined, dried over sodium sulphate and evaporated which gave 20 mg of pure product (yield 99%).

Example 111

(268) ##STR00162##

Cyclopropanesulphonic acid {17-[2-(2-isopropylamino-thiazol-4-yl)-7-methoxy-quinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diaza-tricyclo[(13.3.0.0*4,6*]octadec-7-ene-4-carbonyl} amide (111)

(269) The acid 110 (20 mg, 0.15 mmol), DMAP (28 mg, 0.225 mmol) and EDAC (58 mg, 0.3 mmol) was dissolved in DMF (1.5 mL). The reaction mixture was stirred overnight at R.T. whereafter cyclopropylsulphonamide (91 mg, 1.125 mmol) and DBU (114 L, 0.75 mmol) was added. After stirring at RT overnight the reaction mixture was added to 5% citric add and extracted three times with chloroform. The organic phase was dried over sodium sulphate and evaporated. The afforded residue was purified by preparative HPLC to give the title product (5.6 mg) (yield 24%).

(270) Assays

(271) The compounds of the invention are conveniently assayed for activity against the NS3 protease of flavivirus such as HCV using conventional in vitro (enzyme) assays or cell culture assays.

(272) A useful assay is the Bartenshlager replicon assay disclosed in EP 1043399. An alternative replicon assay is described in WO 03064416.

(273) A convenient enzyme assay involving the inhibition of full-length hepatitis C NS3 is essentially as described in Poliakov, 2002 Prot Expression & Purification 25 363 371.

(274) Briefly, the hydrolysis of a depsipeptide substrate, Ac-DED(Edans)EEAbu.sub.[COO]ASK(Dabcyl)-NH.sub.2 (AnaSpec, San Jos, USA), is measured spectrofluorometrically in the presence of a peptide cofactor, KKGSVVIVGRIVLSGK, as described by Landro, 1997 Biochem 36 9340-9348. The enzyme (1 nM) is incubated in a buffer such as 50 mM HEPES, pH 7.5, 10 mM DTT, 40% glycerol, 0.1% n-octyl--D-glucoside, with 25 M cofactor and inhibitor at say 30 C. for 10 min, whereupon the reaction is initiated by addition of substrate, typically 0.5 M substrate. Inhibitors are typically dissolved in DMSO, sonicated for 30 s and vortexed. The solutions are generally stored at 20 between measurements.

(275) An alternative enzyme assay is described in WO 0399316 and employs an HCV NS3/4A protease complex FRET peptide assay. The purpose of this in vitro assay is to measure the inhibition of HCV NS3 protease complexes, derived from the BMS, H77C or J4168 strains, as described below, by compounds of the present invention. This assay provides an indication of how effective compounds of the present invention would be in inhibiting HCV proteolytic activity.

(276) Serum is taken from an HCV-infected patient. An engineered full-length cDNA template of the HCV genome (BMS strain) was constructed from DNA fragments obtained by reverse transcription-PCR (RT-PCR) of serum RNA and using primers selected on the basis of homology between other genotype I a strains. From the determination of the entire genome sequence, a genotype I a was assigned to the HCV isolate according to the classification of Simmonds et al. (See P Simmonds, K A Rose, S Graham, SW Chan, F McOmish, B C Dow, E A Follett, P L Yap and H Marsden, J. Clin. Microbiol., 31(6), 1493-1503 (1993)). The amino add sequence of the nonstructural region, NS2-58, was shown to be >97% identical to HCV genotype Ia (H77C) and 87% identical to genotype Ib (J4L6S). The infectious clones, H77C (I a genotype) and J4L6S (b genotype) can be obtained from R. Purcell (NIH) and the sequences are published in Genbank (AAB6703, see Yanagi, M., Purcell, R. H., Emerson, S. U. and Bukh. Proc. Natl. Acad. Sd. U.S.A. 94 (16) 8738-8743 (1997); AF054247, see Yanagi, M., St Claire, M., Shapiro, M., Emerson, S. U., Purcell, R. H. and Bukhj, Virology 244 (1), 161 (1998)).

(277) The BMS, H77C and J4L6S strains are conventional for production of recombinant NS3/4A protease complexes. DNA encoding the recombinant HCV NS3/4A protease complex (amino acids 1027 to 1711) for these strains were manipulated as described by P. Gallinari at al. (see Gallinari P, Paolini C, Brennan D, Nardi C, Steinkuhler C, De Francesco R. Biochemistry. 38(17):562032, (1999)). Briefly, a three-lysine solubilizing tall was added at the 3-end of the 3 0 NS4A coding region. The cysteine in the P1 position of the NS4A-NS4B cleavage site (amino acid 1711) was changed to a glycine to avoid the proteolytic cleavage of the lysine tag. Furthermore, a cysteine to serine mutation can be introduced by PCR at amino acid position 1454 to prevent the autolytic cleavage in the NS3 helices domain. The variant DNA fragment can be cloned in the pET21b bacterial expression vector (Novagen) and the NS34A complex can be expressed in Escherichia coli strain BL21 (DE3) (invitrogen) following the protocol described by P. Gallinari et a. (see Gallinari P, Brennan D, Nardi C, Brunetti M, Tomei L, Steinkuhler C, De Francesco R., J Virol. 72(8):6758-69 (1998)) with modifications. Briefly, NS3/4A expression can be induced with 0.5 mM isopropyl beta-D thiogalactopyranoside (IPTG) for 22 hr at 20C. A typical fermentation (I0 I) yields approximately 80 g of wet cell paste. The cells are resuspended in lysis buffer (IO mL/g) consisting of 25 mM N-(2Hydroxyethyl)Piperazine-N-(2-Ethane Sulfonic acid) (HEPES), pH7.5, 20% glycerol, 500 mM Sodium Chloride (NaCl), 0.5% Triton-X100, I ug/mL lysozyme, 5 mM Magnesium Chloride (MgCl.sub.2), I ug/mL Dnasel, 5 mM beta-Mercaptoethanol (BME), Protease inhibitorEthylenediamine Tetraacetic acid (EDTA) free (Roche), homogenized and incubated for 20 mine at VC. The homogenate is sonicated and clarified by ultra-centrifugation at 235000 g for 1 hr at 4 C.

(278) Imidazole is added to the supernatant to a final concentration of 15 mM and the pH adjusted to 8. The crude protein extract is loaded on a Nickel Nitrilotriacetic add (Ni-NTA) column pre-equilibrated with buffer B (25n-tM 2.0 HEPES, pH8 20% glycerol, 500 mM NaCl, 0.5% Triton-XIOO, 15 mM imidazole, 5 mM BME). The sample is loaded at a flow rate of 1 mL/min. The column is washed with 15 column volumes of buffer C (same as buffer B except with 02% Triton-X100). The protein s eluted with 5 column volumes of buffer D (same as buffer C except with 200 mM imidazole).

(279) NS3/4A protease complex-containing fractions are pooled and loaded on a desalting column Superdex-S200 pre-equilibrated with buffer D (25 MM HEPES, pH7.5, 20% glycerol, 300 mM NaCl, 0.2% Triton-XIOO, IO mM BME). Sample is loaded at a flow rate of ImUmin. NS3/4A protease complex3 0 containing fractions are pooled and concentrated to approximately 0.5 mg/mL The purity of the NS3/4A protease complexes, derived from the BMS, H77C and J4L6S strains, are typically judged to be greater than 90% by SDS-PAGE and mass spectrometry analyses.

(280) The enzyme is generally stored at 80C, thawed on ice and diluted prior to use in assay buffer. The substrate used for the NS3/4A protease assay, is conveniently RET S 1 (Resonance Energy Transfer Depsipeptide Substrate; AnaSpec, inc. cat #22991)(FRET peptide), described by Taliani at al. in Anal. Biochem. 240(2):6067 (1996). The sequence of this peptide is loosely based on the NS4A/NS4B natural cleavage site except there is an ester linkage rather than an amide bond at the cleavage site. The peptide substrate is incubated with one of the three recombinant NS3/4A complexes, in the absence or presence of a compound of the present invention, and the formation of fluorescent reaction product was followed in real time using a Cytofluor Series 4000. Useful reagents are as follow: HEPES and Glycerol (Ultrapure) can be obtained from GIBCO-BRL. Dimethyl Sulfoxide (DMSO) is obtained from Sigma. Beta-Mercaptoethanol is obtained from Bio Rad.

(281) Assay buffer: 50 m.M HEPES, pH7.5; 0.15M NaCl; 0.1% Triton; 15% Glycerol; 10 mM BME. Substrate: 2 uM final concentration (from a 2 mM stock 2 0 solution in DMSO stored at 20C). HCV NS3/4A type Ia (Ib), 2-3 nM final concentration (from a 5 uM stock solution in 25 mM HEPES, pH7.5, 20% glycerol, 300 m.M NaCl, 0.2% Triton-X100, 10 mM BME). For compounds with potencies approaching the assay limit, the assay can be made more sensitive by adding 50 ug/mL BSA to the assay buffer and/or reducing the end protease concentration to 300 pM.

(282) The assay is conveniently performed in a 96-well polystyrene black plate from Falcon. Each well contains 25 ul NS3/4A protease complex in assay buffer, 50 ul of a compound of the present invention in 10% DMSO/assay buffer and 25 ul substrate in assay buffer. A control (no compound) is also prepared on the same assay plate. The enzyme complex is mixed with compound or control solution, typically for 1 min before initiating the enzymatic reaction by the addition of substrate. The assay plate is generally read immediately using a spectrophotometer such as a Cytofluor Series 4000 (Perspective Biosystems). The instrument is conveniently set to read an emission of 340 nm and excitation of 490 nm at 25C. Reactions are generally followed for approximately 15 minutes.

(283) The percent inhibition can be calculated with the following equation.
100.[(dF.sub.inh/dF.sub.con)100]
where dF is the change in fluorescence over the linear range of the curve. A nonlinear curve fit is applied to the inhibition-concentration data, and the 50% effective concentration (IC.sub.50) is calculated by the use software such as Excel XI-fit software using the equation:
y=A+((BA)(1+((C/x)^D))).

(284) Enzyme assays conveniently utilize a fluorescence resonance energy transfer (FRET) principle to generate a spectroscopic response to an HCV NS3 serine protease catalyzed NS4A/48 cleavage event. The activity is typically measured in a continuous fluorometric assay using an excitation wavelength of 355 nm and emission wavelength of 500 nm. The initial velocity may be determined from 10 minutes continuous reading of increased fluorescence intensities as a result of the NS3 protease catalyzed cleavage event.

(285) An alternative enzyme assay can be carried out as follows:

(286) Materials

(287) Recombinant HCV NS3 full length enzyme can be prepared as shown in Poliakov at at Protein Expression & purification 25 (2002) 363-371. The NS4A cofactor conveniently has an amino acid sequence of KKGSVVIVGRIVLSGK (commercially available), generally prepared as a 10 mM stock solution in DMSO. The FRET-substrate (Ac-Asp-Glu-Asp(EDANS)-Glu-Glu-Abu--(COO)Ala-Ser-Lys(DABCYL)-NH2, MW1548.60 can be purchased from AnaSpec RET S1, CA. USA) and is typically prepared as a 1.61 mM stock solution in DMSO. Aliquots (50 l/tube) should be wrapped with aluminum foil to protect from direct light and stored in 20 C.

(288) Reference compound-1, N-1725 with a sequence of AcAsp-D-Gla-Leu-Ile-Cha-Cys, MW 830.95 may be purchased from BACHEM, Switzerland and is generally prepare as a 2 mM stock solution in DMSO and stored in aliquots in 20 C.

(289) 1M HEPES buffer may be purchased from invitrogen Corporation, storage at 20 C. Glycerol may be purchased from Sigma, 99% purity.

(290) CHAPS, 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate: may be purchased from Research Organics, Cleveland, Ohio 44125, USA. MW614.90 DTT, DL-Dithiothreitol (Cleland Reagent DL-DT) 99% purity, MW.1542 Storage: +4 C.

(291) DMSO may be purchased from SDS, 13124 Peypin, France. 99.5% purity.

(292) TRIS, ultra pure (TRIS-(hydroxymethylaminomethane), may be purchased from ICN Biomedicals Inc.

(293) Sodium Chloride, may be obtained from KEBOlab AB.

(294) N-dodecyl--maltoside, minimum 98%, may be purchased from Sigma, storage 20 C.

(295) Equipment

(296) Microtiter plates (white clinlplate, ThermoLab Systems cat no. 9502890

(297) Eppendorf pipettes

(298) Biohit pipette, multi dosing

(299) Ascent fluorimeter, flterpai ex 355 nm, em500 nm

(300) Method

(301) Experimental Procedure:

(302) 10 mM stack solutions of the compounds are made in DMSO. The stock solutions are stored in room temperature while testing and placed in 20 C. at long-time storage.

(303) Assay Buffer A:

(304) 50 mM HEPES buffer, pH=7.5, 40% Glycerol, 0.1% CHAPS

(305) Storage: room temperature.

(306) 10 mM DTT (stored in aliquots at 20 C. and added fresh at each experiment)

(307) Assay Buffer B:

(308) 25 mM TRIS pH7.5, 0.15 M NaCl, 10% glycerol, 0.05% n-dodecyl--D-maltoside

(309) 5 mM DTT (stored in aliquots at 20 C. and added fresh at each experiment)

(310) Assay Sequence:

(311) Preparation of Reaction Buffer (for One Date. 100Reactions)(Buffer A)

(312) 1. Prepare 9500 l assay buffer (HEPES, pH=7.5, 40% glycerol and 0.1% CHAPS in de ionized water. Add DTT giving a final concentration of 10 mM (freshly prepared for every run).

(313) 2. Thaw rapidly the NS3 protease

(314) 3. Add 13.6 l NS3 protease and 13.8 l NS4A peptide and mix properly. Leave the mixture for 15 minutes in room temperature.

(315) 4. Place the enzyme stock solution back into liquid nitrogen or 80 C. as soon as possible.

(316) Preparation of Reaction Buffer (for One Plate, 100Reactions) (Buffer B)

(317) 5. Prepare 9500 l assay buffer (TRIS, pH=7.5, 0.16 M NaCl, 0.5 mM EDTA, 10% glycerol and 0.05% n-dodecyl -D-maltoside in de ionized water. Add DTT giving a final concentration of 5 mM (freshly prepared for every run).

(318) 6. Thaw the NS3 protease rapidly.

(319) 7. Add 27.2 l NS3 protease and 13.6 l NS4A peptide and mix property. Leave the mixture for 15 minutes in room temperature.

(320) 8. Place the enzyme stock solution back into liquid nitrogen or 80 C. as soon as possible.

(321) Preparation of Inhibitor/Reference Compound

(322) Make a dilution series of the inhibitors in DMSO to 100 the final concentrations 10, 1, 0.1, 0.01 and 0.001 M. The final DM80 concentration in 100 l total reaction volume is 1%.

(323) Make a dilution series of the reference compound, N-1725 in DMSO to 100 the final concentrations 120, 60, 30, 15, 7.5 and 3.75 nM.

(324) Eight enzyme control wells are needed for every run.

(325) Blank wells contain 95 L buffer (without NS3 PR), 1 L DMSO and 5 L substrate.

(326) Preparation of FRET Substrate

(327) Dilute the substrate stock solution (1.61 mM) with assay buffer to 40 M working solution. Avoid exposure to light.

(328) Assay Sequence

(329) Use 96-well cliniplate, the total assay volume per well is 100 l.

(330) 1. Add 95 L of assay buffer to each well

(331) 2. Add 1 l inhibitor/reference compound

(332) 3. Pre incubate for 30 minutes at room temperature

(333) 4. Start the reaction by adding 5 L 40 M substrate solution (final concentration 2 M)

(334) 5. Read continuously for 20 minutes at ex=355 nm and em=500 nm, monitoring the increased fluorescence per minute.

(335) 6. Plot the progression curve (within linear range, 8-10 time points) and determine the slope as an initial velocity with respect to each individual inhibitor concentration.

(336) 7. Calculate % inhibition with respect to enzyme control.

(337) Treatment of Results

(338) The result is expressed as % inhibition at a certain concentration (screen) or as a Ki value in nM or M.

(339) Calculation of % inhibition: The initial velocity is determined from 10 minutes continuous reading of increased fluorescence intensities as a result of the NS3 protease catalyzed cleavage event. The change in slope for the inhibitor compared to the enzyme control gives the % inhibition at a certain concentration.

(340) Calculation of Ki: All inhibitors are treated as if they follow the rules of competitive inhibition. The IC.sub.50 value is calculated from the inhibition values of a series of inhibitor concentrations. The calculated value it used in the following equation: K.sub.i=IC.sub.50/(1+S/Km)

(341) Plotting of the graph is done by help of two calculation programs: Grafit and Graphpad

(342) Various compounds of the invention exemplified above displayed IC.sub.50s in the range 1 nM to 6.9 micromolar and ED.sub.50s in the sub-micromolar to micromolar range in the above assays.

(343) Drug Escape Resistance Pattern and Rate

(344) Replicon cultures in microtitre plates can be used to determine resistance development rates and to select out drug escape mutants. The compounds being tested are added at concentrations around their ED.sub.50 using, say, 8 duplicates per concentration. After the appropriate replicon incubation period the protease activity in the supernatant or lysed cells is measured.

(345) The following procedure is followed at subsequent passages of the cultures. Virus produced at the concentration of test compound showing >50% of the protease activity of untreated infected cells (SIC, Starting Inhibitory Concentration) are passaged to fresh replicon cultures. An aliquot, say, 15 l supernatant from each of the eight duplicates are transferred to replicon cells without the test compound (control) and to cells with test compound at the same concentration, and additionally two respectively fivefold higher concentrations. (See the table below) When the viral component of replicon propagation (for example as measured by HCV protease activity) is permitted at the highest non-toxic concentration (5-40 M), 2-4 parallel wells are collected and expanded to give material for sequence analysis and cross-wise resistance.

(346) Key:

(347) Viral Growth Emitted

(348) Virus production inhibited

(349) TABLE-US-00001 Pass 1 Pass 2 Pass 3 Pass 4 Pass 5 SIC No compound SIC No compound 5 SIC SIC 25 SIC 5 SIC No compound 25 SIC 5 SIC No compound 25 SIC 5 SIC 125 SIC 25 SIC 125 SIC

(350) Alternative methods for assessing activity on drug escape mutants include the preparation of mutant enzyme bearing the distinctive mutation for use in standard Ki determinations as shown above. For example WO 04/039970 describes constructions allowing access to HCV proteases bearing the 155, 156 and/or 168 drug escape mutants arising from the selective pressure of BILN-2061 and VX-950. Such constructs can then be engineered into replicon vectors in place of the wild type protease, thereby allowing ready assessment in a cellular assay, of whether a given compound is active against a give drug escape mutant.

(351) P450 Metabolism

(352) The metabolism of compounds of the invention through the main isoforms of the human cytochrome system P450 are conveniently determined in baculovirus infected insect cells transfected with human cytochrome P450 cDNA (supersomes) Gentest Corp. Woburn USA.

(353) The test compounds at concentrations 0.5, 5 and 50 M are incubated in duplicate in the presence of supersomes overexpressing various cytochrome P450 isoforms, including CYP1A2+P450 reductase, CYP2A6+P450 reductase, CYP2C9-Arg 144+P450 reductase, CYP2C19+P450 reductase, CYP2D6-Val 374+P450 reductase and CYP3A4+P 450 reductase. Incubates contain a fixed concentration of cytochrome P450 (eg 50 pmoles) and are conducted over 1 hour. The involvement of a given isoform in the metabolism of the test compound is determined by UV HPLC chromatographically measuring the disappearance of parent compound.